


Biomaterials Science

Volume 9
Number 4
21 February 2021
Pages 1053-1468

rsc.li/biomaterials-science



ISSN 2047-4849

REVIEW

View Article Online
View Journal | View Issue



Cite this: *Biomater. Sci.*, 2021, **9**, 1065

Revisiting gene delivery to the brain: silencing and editing

João Conniot,^{†a,b} Sepehr Talebian,^{†c,d} Susana Simões,^{†e} Lino Ferreira^{†*e,f} and João Conde^{†a,b}

Neurodegenerative disorders, ischemic brain diseases, and brain tumors are debilitating diseases that severely impact a person's life and could possibly lead to their demise if left untreated. Many of these diseases do not respond to small molecule therapeutics and have no effective long-term therapy. Gene therapy offers the promise of treatment or even a cure for both genetic and acquired brain diseases, mediated by either silencing or editing disease-specific genes. Indeed, in the last 5 years, significant progress has been made in the delivery of non-coding RNAs as well as gene-editing formulations to the brain. Unfortunately, the delivery is a major limiting factor for the success of gene therapies. Both viral and non-viral vectors have been used to deliver genetic information into a target cell, but they have limitations. Viral vectors provide excellent transduction efficiency but are associated with toxic effects and have limited packaging capacity; however, non-viral vectors are less toxic and show a high packaging capacity at the price of low transfection efficiency. Herein, we review the progress made in the field of brain gene therapy, particularly in the design of non-toxic and trackable non-viral vectors, capable of controlled release of genes in response to internal/external triggers, and in the delivery of formulations for gene editing. The application of these systems in the context of various brain diseases in pre-clinical and clinical tests will be discussed. Such promising approaches could potentially pave the way for clinical realization of brain gene therapies.

Received 31st July 2020,
Accepted 23rd November 2020
DOI: 10.1039/d0bm01278e
rsc.li/biomaterials-science

1. Introduction

The concept of gene therapy relies on the delivery of recombinant nucleic acids (DNA or RNA) to add, replace, repair, or even remove a gene sequence. The delivery of nucleic acids induces a change in the cell phenotype, which, in case of disease, means slowing down the disease progression or leads to the cure. Although the idea may seem extremely simple, gene regulation is highly complex, and many diseases result from a pattern of multiple altered genes, like some neurodegenerative diseases, such as Alzheimer's and Parkinson's dis-

eases. Gene therapy can also be used to target cancer cells, by introducing a gene that will induce a phenotype more susceptible to complementary therapeutic strategies or is directly lethal. Even though the translation of gene therapy started in the early 1990s, the lack of knowledge concerning gene vectors, target cells, and, in particular, the diseases, has led to disappointing outcomes.^{1,2} In the beginning of the 2000s, the development of new vectors and gene-editing tools, combined with a deeper understanding of the target cells, renewed interest, and new trials evidenced sustained genetic modifications and clinical benefits in some.^{3–5}

RNA interference (RNAi), by which disease genes can be specifically silenced, has great potential to become a successful therapeutic strategy for neurological diseases.⁶ Small interfering RNAs (siRNAs) and microRNAs (miRNAs) have attracted considerable attention due to their role in gene regulation, which makes them likely targets for drug discovery and development.⁷ Therapeutic approaches based on siRNA involve the introduction of a synthetic siRNA into the target cells to elicit RNA interference (RNAi), thereby inhibiting the expression of a specific messenger RNA (mRNA) to produce a gene-silencing effect. By contrast, miRNA-based therapeutics comprise two approaches: miRNA inhibition and miRNA replacement.⁸ miRNA inhibition resembles antisense therapy, with synthetic

^aNOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal. E-mail: joao.conde@nms.unl.pt

^bCentre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal

^cIntelligent Polymer Research Institute, ARC Centre of Excellence for Electromaterials Science, AIIM Facility, University of Wollongong, NSW 2522, Australia

^dIllawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW 2522, Australia

^eCNC – Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal. E-mail: lino@uc-biotech.pt

^fFaculty of Medicine, University of Coimbra, 3030-789 Coimbra, Portugal

[†]These authors contributed equally.

single-stranded RNAs acting as miRNA antagonists (also known as antagomirs or anti-miRs) to inhibit the action of the endogenous miRNAs. On the other hand, in the replacement approach, synthetic miRNAs (also known as miRNA mimics) are used to mimic the function of the endogenous miRNAs, which leads to mRNA degradation/inhibition and produces a gene-silencing effect.⁹ In any case, the use of RNAi is limited to targets for which gene knockdown is beneficial. Also, RNAi often cannot fully repress gene expression and is therefore unlikely to provide a benefit for diseases in which complete ablation of gene function is necessary for therapy.¹⁰ Consequently, genome-editing technologies based on programmable nucleases, such as zinc finger nucleases (ZFNs),¹¹ transcription activator-like effector nucleases (TALENs),^{12,13} and the clustered regularly interspaced short palindromic repeat (CRISPR)-associated nuclease Cas9,¹⁴ are opening up the possibility of therapeutic genome editing in diseased cells and tissues, resulting in the removal or correction of deleterious mutations or the insertion of protective mutations.

Growing interest in gene therapy has been motivated by the fact that, in theory, gene-based approaches may provide, with a single treatment, a sustained production of endogenous proteins by the target cells, which obviates the need for repeated administration of protein-based therapies. However, genetic manipulation of the CNS presents many challenges. The specific characteristics of most neurons, which are terminally differentiated, require specific delivery strategies, such as vectors that persist in postmitotic cells. In terms of gene therapy, which has shown promising results for the treatment of several diseases of the CNS, such as lysosomal storage diseases,¹⁵ Parkinson's disease,¹⁶ Alzheimer's disease,¹⁷ and brain tumors,¹⁸ gene delivery after systemic administration remains one of the main challenges, largely due to the blood-brain barrier (BBB).¹⁹ Before we achieve widespread application of gene delivery to the brain and the nervous system, specifically in the clinic, further efforts must be made to fine-tune targeted strategies and guarantee their safety and efficacy.

Herein, we review the most recent advances in brain gene delivery focusing on silencing and editing. Although recent studies have reviewed aspects of brain gene therapies,^{20,21} they were limited in integrating both silencing and editing strategies and cover non-viral delivery systems. Initially, we will

highlight gene-delivery strategies to the brain using viral vectors (*e.g.* adenovirus, lentivirus, herpes simplex virus) and non-viral vectors (*e.g.* cationic liposomes, cationic polymers, organic and inorganic nanomaterials). Then, the importance of silencing gene therapies to treat brain diseases such as cancer and neurodegenerative diseases will be discussed. Finally, we will cover brain gene-editing strategies focusing essentially on the CRISPR/Cas system.

2. Gene-delivery strategies to the brain

Many chronic neurologic diseases do not respond to small-molecule therapeutics and have no effective long-term therapy.²² Gene therapy offers the promise of an effective cure for both genetic and acquired brain disease, yet progress in clinical trials has been slow, and a major limiting factor is delivery of the gene to brain.²³ This is primarily due to complexity of the brain, side effects, and the impermeable blood-brain barrier (BBB).²⁴ To this end, various vectors (vehicles) were used to move genetic information into a target cell, which mainly included viral and non-viral vectors (see Fig. 1).^{25,26} Each type of vector imposes its own set of advantages and disadvantages, and hence in the following section we will provide a comprehensive description of each vector type accompanied by relevant examples where they were used for gene delivery to brain.

2.1. Viral vectors

Ideal virus-based vectors for most gene-therapy applications harness the viral infection pathway but avoid the subsequent expression of viral genes that leads to replication and toxicity.²⁷ In particular, the viral particles encapsulate a modified genome carrying a therapeutic gene cassette in place of the viral genome.²⁸ Features of the ideal viral vector are: (i) specific tropism for highly efficient transduction of the target tissue and minimal transduction of 'off-target' cells, tissues, or organs; (ii) capacity to express the transgene for a period of time and at a level so as to have maximal therapeutic impact while eliciting a minimal host immune response; (iii) minimal side effects such as vector-related pathologies and/or host immune response.²⁶ The spectrum of viral vectors used in




Fig. 1 Schematic representation of viral (left) and non-viral (right) vector for gene delivery to the brain.

basic research applications includes viruses with simple capsid virions—such as recombinant adenovirus and adeno-associated virus—and others such as retrovirus/lentivirus, and herpes virus, in which the capsid is surrounded by a lipid bilayer envelope.²⁹ The difference between each class of viral vectors is their packaging capacity, transduction capability, integration into the host genome, duration of transgene expression, and induced pathogenesis, to name just a few.³⁰ It should be noted that vectors derived from some retroviruses, such as Moloney murine leukaemia virus (MoMLV), have limited applications as vectors for the central nervous system (CNS) owing to their inability to deliver genes to non-dividing cells. Retroviral vectors have successfully been applied to modify non-neuronal cells *ex vivo* prior to transplantation in the nervous system.³¹ However, adeno-associated virus, lentivirus, and herpes virus are all suitable vectors to efficiently transduce neurons of the CNS.²⁶ Nonetheless, because of the properties of binding and entry proteins on the virus capsid or envelope, some cells are intrinsically more susceptible to infection with certain vectors. Also, depending on the viral type, it can interact with different target cell receptors, which correspondingly mediates a different mechanism of endocytosis.³² Overall, viral vector delivery modalities can be grouped into those that attempt to achieve widespread gene delivery throughout the brain (global) and those that target specific cell populations within the brain (focal). Accordingly, focal delivery is often achieved through local administration where vectors are either injected directly into the brain parenchyma, ventricles, or vasculature, or indirectly injected *via* intrathecal or intranasal administration, with different types of vectors and modes of injection designed to hit selected targets.²⁹ Local administration of these viral vectors implies that focal delivery modalities are capable of bypassing BBB, and they are also less susceptible to neutralization by circulating antibodies.³³ Conversely, methods for global delivery include injection into the carotid artery, with promotion of entry across the blood–brain barrier through localized disruption of BBB (using magnetic resonance-guided focused ultrasound and IV administered microbubbles) or receptor-mediated transport *via* transcytosis (using the transferrin receptor, LDL receptor-related proteins, or insulin receptor), or using a viral vector that naturally crosses the BBB (archetypally, AAV9).³⁴ The type of brain disease can determine the suitable method of viral delivery. For instance, focal delivery is preferred for treatment of Parkinson's disease by targeting focal areas of disease pathogenesis, whereas global delivery is more appropriate for widespread CNS diseases, such as brain tumors and lysosomal storage diseases.³⁵ Currently, viral vector-mediated gene therapy for disorders of the central nervous system is focused on life-threatening or severely debilitating diseases, owing in part to unknown risk factors associated with virus vectors. Neurological conditions where these vectors might prove to be effective include stroke, spinal cord injury, neurodegenerative diseases, lysosomal storage diseases, brain tumours, and pain.²⁹ In the following section, we will review the most common viral vectors used for gene delivery to the brain.

2.1.1 Adenoviruses. The most frequently applied viral vectors are certainly those based on adenoviruses, in which naked dsDNA adenoviruses possess a packaging capacity of 7.5 kb of foreign DNA providing short-term episomal expression of the gene of interest in a relatively broad range of host cells.³⁶ Natural and acute immunologic responses against adenoviruses have limited their clinical application, and so these vectors have experienced several generational steps of development.³⁷ First-generation vectors contained deletions of the E1 and/or E3 regions of the genome, the former encoding proteins necessary for early gene expression and the latter being dispensable for replication and packaging. This endowed a transgene capacity of up to ~8.3 kb, but this generation of vectors retained a majority of the viral genes, and cytotoxicity associated with expression of the viral genes has hindered their application.²⁶ To this end, second-generation vectors had more extensive deletions of the adenoviral sequence, removing the E2 or E4 regions along with E1/3. The corresponding deletions on the viral genome allowed the insertion of expression cassettes up to 14 kb. However, second-generation adenoviruses vectors still did not avoid *in vivo*-associated immunogenicity and toxicity due to residual gene expression from the remaining viral genes.³⁸ The last generation, namely “Gutless” adenoviruses, are completely devoid of viral coding sequences, bringing their cloning capacity to 36 kb, but require sophisticated production systems involving a helper virus capable of providing *in trans* all necessary elements for encapsidation. The host immune response against helper-dependent vectors is reduced compared with that of earlier-generation vectors but still remains a problem. Regardless, helper-dependent adenoviral vectors have been shown to transduce neuronal, astroglial, and human glioma cells, demonstrating that targeting of neuronal tissues is possible with these vectors.^{39,40} Accordingly, transgenes that encode therapeutic proteins^{41–44} have been successfully delivered to the CNS using helper-dependent or recombinant adenoviruses, to facilitate glioblastoma treatment and neural functional recovery, and reduce the inflammatory response of astrocytes.

2.1.2 Adeno-associated virus. Adeno-associated virus (AAV) is a protein capsid surrounding and protecting a small, single-stranded DNA genome of approximately 4.8 kilobases (kb). AAV belongs to the parvovirus family and is dependent on co-infection with other viruses, mainly adenoviruses, in order to replicate. The single-stranded DNA of AAVs comprises the *rep* gene (genome replication and virion assembly) and the *cap* gene (gives rise to the viral capsid proteins) flanked by two inverted terminal repeats (ITRs). The capsid is made up of viral capsid proteins VP1, VP2, and VP3, which facilitate binding of the virion to the cell surface receptor and varies between serotypes. Generally, the cell tropism and regional transduction pattern of AAV in the CNS depend on the AAV capsid.⁴⁵ For instance, AAV1, AAV2, AAV4, AAV5, AAV7, AAV8, AAV9, and rh.10 capsids have been studied by multiple laboratories for transduction and tropism in the CNS in several pre-clinical species.^{21,46} One downside of AAV vectors is that their global delivery in humans is often subjected to pre-existing

neutralizing antibody (NAb) against assembled AAV capsid in the circulation, which can potentially compromise or abrogate transduction.⁴⁷ The other disadvantages of AAV vectors are the complicated process of vector production and the limited transgene capacity of the particles (<5 kb).⁴⁸

Nevertheless, adeno-associated virus (AAV) and recombinant AAV vectors are commonly used to deliver various genes to brain mainly due to their favourable attributes such as capability to infect both dividing and non-dividing cells, as well as their minimal immunogenicity.⁴⁹ Along similar lines, transgenes that encode therapeutic proteins,^{50–55} microRNAs (miRNAs),^{56–60} antibodies,^{61–63} and CRISPR-Cas9 guide RNA for gene editing^{64–68} have been successfully delivered to the

CNS with AAVs in mice and other species (Fig. 2A). In addition, multiple capsids have been used across species to successfully target a variety of tissues and cell types within the CNS, including neurons, astrocytes, oligodendrocytes, and glioma cells.^{45,69–74}

2.1.3 Lentivirus. Lentiviruses are a subclass of retroviruses. They have recently been used as gene-delivery vectors due to their ability to integrate naturally with non-dividing cells, which is the unique feature of lentiviruses, as compared with other retroviruses, which can infect only dividing cells.⁷⁵ In fact, most lentiviral vectors (LVVs) are derived from the human immunodeficiency virus (HIV) type 1 and retain the ability to integrate into the genome of infected cells, which is a powerful




Fig. 2 Viral and non-viral delivery for gene silencing in brain, (A) AAV-mediated SOD1 silencing by overexpression of miRNA against human SOD1 coding sequence, to prevent motoneuron degeneration caused by SOD1 mutation. Reproduced with permission.¹⁸⁸ Copyright 2015, Wiley. (B) Lentivirus-mediated miRNA-guided neuron tag ("mAGNET") to restrict transgene expression to cortical inhibitory (GABA+) neurons in the mouse neocortex (GABA mAGNET). Reproduced with permission.¹⁸⁹ Copyright 2018, Elsevier. (C) RNAi therapy for human glioblastoma *in vivo* using siRNA-loaded nontoxic brain-targeting chimaeric polymersomes (ANG-CP-siRNA). Reproduced with permission.¹⁹⁰ Copyright 2018, Elsevier. (D) A cyclic peptide iRGD (CCRGDKGPDC)-conjugated solid lipid nanoparticle (SLN) to deliver small interfering RNAs (siRNAs) against both epidermal growth factor receptor (EGFR) and PD-L1 for combined targeted and immunotherapy against glioblastoma. Reproduced with permission.¹³⁸ Copyright 2019, American Chemical Society. (E) Targeted delivery of theranostic polyfunctional gold-iron oxide nanoparticle (polyGION) surface loaded with therapeutic miRNAs (miR-100 and anti-miR-21) to glioblastoma in mice. Reproduced with permission.¹⁷⁷ Copyright 2019, Elsevier.

technique that allows scientists to manipulate genes and gene expression.⁷⁶ Although these vectors do not naturally infect cells of the CNS, there is significant potential for modifying tissue tropism for specific therapeutic applications. Two main approaches have been considered to achieve targeted LV transduction in the CNS. First, it is possible to direct expression to certain cell types by using promoter elements that are active only in the desired cells. For instance, both neuron-specific and glial-specific promoters have been shown to confer cell-type-specific transgene expression in the desired cell-type.^{77,78} However, in some cases, a portion of the integrated transgenes may be non-specifically activated due to positional effects from surrounding genes.⁷⁹ Hence, to address this issue, the second approach was realized by combining the cell-type-specific promoters with envelope proteins that bind to specific receptors found only on the desired cell type. Along these lines, the envelope gene of HIV-1 is, in most cases, replaced by a heterologous gene to alter tropism and specificity.⁸⁰ A large number of various viral envelopes have been used to pseudotype lentiviral vectors, including glycoproteins from various strains of vesicular stomatitis virus (VSV), various strains of Rabies virus, Mokola virus, Lymphocytic choriomeningitis virus (LCMV), Ross River virus, and others.⁷⁹ These viral envelopes do not necessarily warrant specific cell-type tropism, and in most cases they are combined with cell-type-specific promoters to instigate transgene expression in the desired cell type.^{81–83}

Lentiviral vectors can deliver 8 kb of sequence, and that means they can accommodate larger transgenes than AAV vectors.²⁶ Lentiviral vectors have the advantages of high-efficiency infection of dividing and non-dividing cells, long-term stable expression of a transgene, and low immunogenicity.²⁹ Conversely, this powerful tool has the potential to cause oncogenic, infectious, and other transformative changes to infected cells. LVV-infected cells can become cancerous through activation of oncogenes or inactivation of tumor-suppressor genes.⁸⁴ One way to address this is application of the self-inactivating (SIN) vector in which the viral enhancer and promoter sequences have been deleted.^{85,86} Transgenes that encode therapeutic microRNAs (miRNAs),^{87–93} siRNAs,^{94–98} and shRNA^{99–103} have been successfully delivered to the CNS with LVVs in mice (Fig. 2B). LVVs have been demonstrated to transduce most cell types within the CNS *in vivo*, including neurons, astrocytes, adult neuronal stem cells, oligodendrocytes, and glioma cells.⁷⁹ Efficient therapeutic effects of LVV-mediated transgene expression have been documented in animal models of lysosomal storage diseases (LSDs), Alzheimer's disease (AD), ALS, Huntington's disease (HD), and Parkinson's disease (PD), among others.⁷⁹

2.1.4 Herpes simplex virus. Herpes simplex virus (HSV) is a member of *Herpesviridae* and belongs to the subfamily *Alphaherpesvirinae*. Depending on the cellular site of latency, herpesviruses are classified as either HSV-1 or HSV-2.¹⁰⁴ HSV-1 is a common pathogen in humans, causing primarily cold sores, but occasionally encephalitis and other life-threatening conditions, especially in immune-compromised individuals. It is an enveloped virus bearing 152 kb of double-stranded DNA

encoding over 80 genes, which has high infectivity for neurons and glia, as well as many other cell types.³⁵ The HSV-1 genome contains a significant portion of viral genes that are considered “non-essential” and can be deleted without affecting viral replication in cultured cells. These findings have paved the way for the generation of a number of HSV-1-derived vectors: conditionally replicating vectors, replication-defective vectors, and amplicon-based vectors.¹⁰⁵ Conditionally replicating HSV-1 vectors are deficient in expression of viral genes essential for replication in non-dividing cells. Because replication of these vectors is highly toxic to infected cells, they can be used to target proliferating cells for killing. Consequently, they have been typically used in the development of therapies for malignant brain tumors (*e.g.* glioblastoma multiforme, GBM) and are referred to as oncolytic HSV-1 vectors.¹⁰⁶ More extensive removal of viral genes led to the creation of replication-defective vectors, which lack the ability to replicate autonomously and require complementing helper function for propagation. Removal of immediate-early genes, necessary for expression of early and late genes, from these vectors greatly reduced vector toxicity.¹⁰⁷ Identification of the minimal *cis*-acting sequences necessary for virus replication, the cleavage/packaging signal and the viral origin, provided another significant advancement in the design of HSV vectors.²⁶ Amplicon vectors contain only these elements and have a packaging capacity of ~150 kb.²⁹ These vectors have several advantages over attenuated or replication-defective vectors, including a lack of viral genes that might cause cytotoxicity, maximal transgene coding capacity, high infectivity for cells of the nervous system, and retention for up to months in non-dividing cells.³⁵ However, the total reliance on helper viruses for amplicon production and packaging makes this platform challenging to manufacture and validate. The production method ultimately leads to cross-contamination of amplicon stocks with variable amounts of helper virus particles that are potentially cytotoxic and immunogenic.¹⁰⁸

HSV-1 is a neurotropic virus that can spread through the nervous system and establish a latent infection in neurons. Although sensory neurons are the natural reservoir of latency, gene-transfer experiments have shown that HSV-1 can also establish a latent infection in other neurons within the brain, as well as motor neurons.¹⁰⁹ Generally, transgenes that encode therapeutic proteins^{110–113} and antibodies^{18,114–116} have been successfully delivered to the CNS with HSVs. Efficient therapeutic effects of HSV-mediated transgene expression have been documented in animal models of Parkinson's disease and brain tumors.¹¹⁷

2.2. Non-viral vectors

Although viral vectors have substantially advanced the field of gene therapy, several limitations are associated with viral vectors, including carcinogenesis, immunogenicity, broad tropism, limited DNA packaging capacity, and difficulty of vector production.¹¹⁸ To this end, non-viral gene therapy has the potential to address many of these limitations, particularly with respect to safety, as it is less immunogenic and non-inte-

grating into the host genome.²⁵ Non-viral vectors also have the potential to deliver larger genetic payloads and are typically easier to synthesize than viral vector.¹¹⁹ Nevertheless, few of these vectors have so far been developed clinically, owing to their low delivery efficiency relative to viral vectors.¹¹⁸ So far, a variety of non-viral vectors were used for gene delivery, including cationic lipids and liposomes, cationic polymers, polypeptides, and organic/non-organic nanoparticles.^{19,25,120–122} In the context of gene delivery, the ideal non-viral vector must target a specific population of cells to deliver its payload of condensed DNA or RNA to mediate an appropriate intracellular delivery of sufficient therapeutic to achieve a functional outcome.²⁵ However, depending on the mode of administration (being systemic or local), the non-viral vectors can face different barriers.

Accordingly, systemically delivered non-viral vectors need to prevent degradation by serum endonucleases and evade immune detection (which could be achieved by chemical modifications of nucleic acids and encapsulation of vectors). They also need to avoid renal clearance from the blood and prevent nonspecific interactions, using polyethylene glycol (PEG), or through specific characteristics of particles.¹¹⁸ Furthermore, for successful gene delivery to CNS, non-viral vectors must also pass the BBB. Accordingly, the structural and physicochemical properties of vectors including molecular size, charge, hydrogen-bonding potential, and lipophilicity will determine which is the passage mechanism across the BBB.¹²³ Accordingly, the following transport mechanisms have been proposed: (i) vectors open tight junctions between endothelial cells or induce local toxic effects, which leads to a localized permeabilization of the BBB allowing the penetration of the cargo conjugated with the vectors (this could also be achieved by osmotic disruption, ultrasound disruption, or magnetic disruption, though they could be detrimental to integrity of the BBB¹²⁴); (ii) vectors pass through endothelial cell by transcytosis (*via* absorptive-, transporter-, or receptor-mediated transcytosis¹²⁵); or (iii) a combination of several of the mechanisms described previously.¹⁹ Moreover, after passage through the BBB, the vectors must selectively target diseased cells while minimizing the distribution into normal brain cells.¹²⁶ Also, following internalization, vectors are challenged with a new set of intracellular obstacles (including endolysosomal escape, transport through the cytoplasm, nuclear localization, and unpacking) that must be overcome for successful gene delivery.¹¹⁹ Nevertheless, in order to achieve effective concentrations in the brain, the vectors must be administered in doses that are associated with adverse effects in peripheral organ.¹²⁷

Consequently, local delivery of non-viral vectors was suggested as an alternative approach to bypass some of the obstacles associated with their systemic delivery. Hence, intraparenchymal (directly into the diseased brain regions facilitated by convection-enhanced delivery or inclusion into biodegradable polymeric implants), intraventricular (into the cerebrospinal fluid produced in the ventricles of the brain), intrathecal (into the intrathecal space surrounding the spinal

cord), and intranasal administrations were practiced as local delivery approaches for delivery genes *via* non-viral vectors to CNS,^{128–130} albeit local delivery approaches are prone to limitations such as local trauma to the brain neuropil that leads to inflammation and toxicity, as well as limited diffusion from the injection site (for the intraparenchymal route), and an ultimate low ratio of successfully delivered vectors to the brain (for intrathecal and intranasal routes).¹³¹

In the following section, we will review the most commonly used non-viral vectors for gene delivery to the brain.

2.2.1 Cationic lipid-based particles. Lipid-based particles are roughly nano- or micro-sized delivery systems consisting of one or more lipid bilayers. Given their unique physicochemical characteristics, lipid-based particles can incorporate lipophilic, hydrophobic, or even hydrophilic therapeutic agents, when the lipid layers surround an aqueous inner compartment.¹³² The phospholipid bilayer in lipid-based particles can facilitate the permeation of drugs across various biological membranes, but this is not enough for crossing the liposome through the BBB. At the same time, the cationic lipid-based particles can cross the BBB *via* absorption-mediated transcytosis, by taking advantage of the BBB's negative charge that facilitates cell internalization processes through electrostatic interactions.¹³³ However, this interaction can change drastically *in vivo* if the cationic lipid-based particles are administered intravenously, due to adsorption of blood proteins and other molecules on the surface of the particles.¹³⁴ Cationic lipids such as *N*-[1-(2,3-dioleoyloxy)propyl]-*N,N,N*-trimethylammonium chloride (DOTMA) are composed of a hydrophilic head group, a hydrophobic tail group, and a linker between these two domains.¹²¹ Particular modification of these three domains can lead to formation of new cationic lipids such as DOSPA, DOTAP, and DMRIE, which have been prevalently used for gene-delivery applications.¹³⁵ In particular, the positively charged head group binds with the negatively charged phosphate group in nucleic acids (such as DNA and RNA) to form a uniquely compacted structure called lipoplexes.⁷⁵ However, the major drawbacks of cationic liposomes are their nonspecific uptake by peripheral tissues, together with their binding to serum proteins, which follows their high dosage administration to reach therapeutic efficacy that can cause toxicity.¹³⁶ To address these issues and further enhance the transfection efficiency of lipoplexes, the addition of helper lipids to the formulations was suggested. Helper lipids can be further categorized accordingly: (i) neutral lipids, (ii) cholesterol (CHOL), (iii) phosphatidylcholine (PC), (iv) PEGylating lipids, (v) anionic lipids, and (vi) non-ionic surfactants.¹³⁷ Furthermore, surface functionalization of lipid-based particles with biologically active ligands, such as peptides, antibodies, or small molecules, which specifically bind to receptors on specific cell lines, can be used to allow targeted delivery of lipid-based particles to different cells within the brain.¹³³ In general, a number of factors can determine the gene-delivery efficiency of cationic lipid-based particles, including the structure of the cationic lipids, the choice of helper lipids and their percentages in the formulation, the lipid-to-nucleic acid ratio and the resulting positive-negative

charge ratio, and the reversibility of PEGylation.¹³⁷ Cationic lipid-based particles were extensively used for delivery of miRNA or siRNA to treat brain tumors in preclinical animal models (Fig. 2C).^{138–144}

2.2.2 Cationic polymers. Cationic polymers are another class of non-viral vectors and are attractive partly due to their large chemical diversity and their potential for functionalization.¹¹⁸ The most significant differences between cationic polymers and cationic lipids are that cationic polymers are mostly hydrophilic, and they can compress nucleic acid molecules to a relatively small size, which could be crucial for improving transfection efficiency.¹⁴⁵ DNA-binding moieties, including primary, secondary, tertiary, and quaternary amines, as well as other positively charged groups such as amidines, can reside in the polymer backbone, in pendant groups, or in grafted oligomers. The polymers themselves could also comprise linear, branched, or dendritic structures.¹¹⁹ Accordingly, polyethylenimine (PEI) and poly(L-lysine) (PLL) have been used extensively for effective gene delivery, but due to their high positive charge, they are associated with moderate to high levels of toxicity, as well as low transfection efficiency.¹⁴⁶ With the aim of improving safety and efficacy, numerous other polymers have been studied for gene delivery, including methacrylate-based polymers such as poly[(2-dimethylamino) ethyl methacrylate] (pDMAEMA), carbohydrate-based polymers such as chitosan and β -cyclodextrin-containing polycations, poly-amidoamine (PAMAM) dendrimers, polypeptides, and degradable polymers such as poly(β -amino ester) and poly[α -(4-aminobutyl)-L-glycolic acid] (PAGA).^{145,147} The endosomal escape capability of cationic polymers, which is essential for efficient gene delivery, can be enhanced *via* membrane-destabilizing mechanisms by incorporating hydrophobic molecules along with pH-responsive polymers into their formulations.^{148,149} Cationic liposomes were extensively used for delivery of shRNA, miRNA, or siRNA to treat cerebral ischemia, Parkinson's disease, Alzheimer's disease, Huntington's disease, and brain tumors in preclinical animal models (Fig. 2D).^{150–171}

2.2.3 Organic and inorganic nanomaterials. Nanomaterials could provide robust protection of nucleic acids from degradation by nucleases, efficient cell entry through the cell membrane, and release of the nucleic acid in its functional form within the nucleus.¹⁷² A number of nanomaterials are used for gene-delivery applications based on polymers (such as PLGA or PCL), graphene, carbon nanotubes, gold nanoparticles, magnetic nanoparticles, quantum dots, and mesoporous silica nanoparticles.^{172,173} Inorganic nanoparticles offer advantages over polymeric nanoparticles in terms of trackability by microscopy techniques (*e.g.* magnetic resonance imaging; MRI), as well as on-demand gene delivery triggered by external stimuli such as light, ultrasound, or magnetic fields.¹⁷⁴ However, inorganic nanoparticles also have disadvantages because they might not be degraded (or eliminated through the kidneys) or present undesirable toxicity.¹⁹ In general, it has been shown that functionalized nanomaterials are the most promising gene-delivery platforms owing to their small size,

targeted delivery of nucleic acids, sustainment of gene-delivery effects in target tissue, and superior stability of the genetic material.¹⁷⁵ In fact, nanomaterial functionalization can be achieved using cationic lipids or polymers, with the aim of enhancing their BBB passage, as well as their transfection efficiency.^{120,175} Organic and inorganic nanomaterials were extensively used for delivery of shRNA, miRNA, or siRNA to treat cerebral ischemia, Parkinson's disease, and brain tumors in preclinical animal models (Fig. 2E).^{176–187}

3 Gene therapy: replacement and silencing

3.1 Gene therapy in inherited diseases

Several innate genetic defects have a deleterious effect on the brain, such as lysosomal storage diseases (LSD). In LSD, the genetic defects lead to lysosomal dysfunction, which results in accumulation of uncleaved lipids, glycoproteins, and/or glycosaminoglycans. As a consequence, cell morphology can be altered by high oxidative stress, marked neuroinflammation, and impaired tissue and organ functions.^{191,192} Current available therapies for LSD are based on enzyme replacement or hematopoietic stem cell transplantation, which are extremely expensive and have unclear long-term effectiveness.¹⁹³ These metabolic inherited diseases are promising candidates for brain gene therapy, because they generally result from a single gene defect, and the non-functional mutated gene can be replaced and the normal phenotype restored. Gene therapy may offer a more affordable, complete treatment to all the conditions in these diseases. Some pre-clinical studies and clinical trials have already shown promising results in different diseases, such as Gaucher disease,¹⁹⁴ mucopolysaccharidosis,^{195,196} and the Niemann-pick type C1 disease,^{197,198} by replacement gene therapy.

3.2 Gene therapy in acquired diseases

Even though the genetic pattern in acquired diseases is much more complex than in single gene inborn defects, gene therapy may also constitute a relevant approach in neurodegenerative conditions, such as Parkinson's (PD) and Alzheimer's (AD) diseases, or in brain tumors.

3.2.1 Parkinson's disease. In PD, there is progressive loss of dopamine (DA) neurons in the substantia nigra, which leads to decreased levels of DA and affects the movement and the body posture. The current therapies are based on the administration of the DA precursor L-dopa, which in long-term treatments results in strong adverse effects that outweigh the benefits.¹⁹⁹

Gene-therapy strategies for PD rely on the transfer of genes encoding neurotransmitter-synthesizing or metabolic enzymes to improve the function of the impaired synthesis. For instance, several approaches have reported the successful transfer cDNA of tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of DA to the striatum. Other genes, which encode complementary enzymes of DA synthesis, such

as the aromatic amino acid decarboxylase (AADC)^{200,201} and the GTP cyclohydrolase (GTPCH)²⁰² have also been delivered and have been shown to maximize DA production in the striatum. Silencing of the *SNCA* (alpha synuclein) gene with siRNA and shRNA has also shown promising results both *in vitro* and *in vivo*, with a reduction in SNCA in the brain and improvement in motor dysfunction.^{203,204} On the other hand, gene therapy can also be used to deliver genes of trophic factors and protective proteins to slow down or block the neurodegenerative process. Some examples of molecules that limit the progression of PD are anti-apoptotic, antioxidants, and trophic peptide factors, such as the glial-derived growth factor (GDNF).^{205–208} Although this protein does not cross the BBB after systemic administration, gene therapy has enabled their delivery to the striatum and substantia nigra, showing promising results.^{208,209}

3.2.2. Alzheimer's disease. AD is a progressive neurodegenerative disease and the most frequent cause of dementia, characterized by memory loss and decrease in cognitive function.²¹⁰ In AD, there is formation not only of beta-amyloid (A β) plaques, extracellularly, but also, in parallel, of intracellular neurofibrillary tangles (NFTs), by deposition of hyperphosphorylated Tau protein. Even though the whole pathological mechanism is still unclear, research has shown that AD is caused by an inflammatory process that results from the combination of genetic and environmental factors.²¹¹

The current available therapies for AD are based on anticholinesterase inhibitors and NMDA antagonists, to improve cognitive function and behavior. However, the efficacy of these drugs has been very limited.²¹² Gene-therapy strategies so far have been focused on reducing Tau phosphorylation and A β plaques. The most obvious target for gene-therapy silencing is the amyloid precursor protein (APP), whose proteolysis leads to increased levels of A β protein. However, this silencing strategy has been avoided due to the role of APP in neuronal development and differentiation.²¹³ Enzymes such as β -secretase, which are responsible for cleaving APP, leading to accumulation of A β protein, have been used as an alternative target. *In vivo* delivery of siRNA to silence β -secretase resulted in less accumulation of beta-amyloid (A β) in the hippocampus, as well as improvements in cognition and memory in mice.¹⁵³ Selective gene silencing of glycogen synthase kinase 3 beta (GSK3 β), an enzyme involved in Tau phosphorylation, induced memory preservation and synaptic plasticity in mice.²¹⁴ In clinical trials, *ex vivo* gene delivery of nerve growth factor (NGF) improved the rate of cognitive decline.^{215,216}

3.2.3. Brain tumors. Despite the advances in chemo and radiotherapy, as well as novel surgical techniques, patients with malignant tumors have a poor prognosis. The limited efficacy of the available therapies has been attributed to genetic mutations in tumor cells, which become resistant and avoid apoptosis.²¹⁷ In general, cancer gene therapy against cancer can be grouped in pro-apoptotic gene therapy, suicide gene therapy, anti-angiogenic gene therapy, immune modulatory gene therapy, siRNA therapy, gene editing, or even oncolytic gene therapy.²¹⁸ In brain tumor therapy, research has been

focused on cytotoxic or immune modulatory strategies. Cytotoxic gene therapy has been based on the delivery of pro-apoptotic genes, such as the p53-upregulated modulator of apoptosis, PUMA,²¹⁹ or Bax,²²⁰ genes that sensitize cells to drugs and radiation,^{221–223} or even genes that modulate angiogenesis.¹¹⁰ Oncolytic viruses, which are intrinsically toxic to tumor cells, have also had promising results as a cytotoxic approach.^{224–226} Transfection of growth arrest-specific 5 (GAS5) suppressed tumor malignancy in glioma by down-regulating microRNA (miR)-222.²²⁷ Ablation of the oncogenic miR-10b using gene editing has shown strong effects on killing both glioma cells and transformed astrocytes.²²⁸ On the other hand, the delivery of genes responsible for immune modulation should increase the immunity towards tumor cells and antigens as well as the cytotoxic activity of immune effector cells. In a pilot clinical trial and pre-clinical studies, gene therapy with IFN- β induced a potent antitumor activity in patients with malignant glioma (Table 1).^{229,230}

4. Brain gene editing

Gene editing has emerged in recent years as a tool in the neurosciences, specifically to investigate the role of genes in normal brain-behaviour relationships, and as a potential therapeutic strategy for some neurodegenerative disorders. These tools rely on nucleases that are able to specifically recognize and induce double-strand DNA breaks (DSBs) at target locations in the genome. Genome editing tools based on site-specific DNA nucleases can include zinc finger nucleases (ZFNs),^{11,242} transcription activator-like effector nucleases (TALENs),^{243,244} and the Cas effector proteins of clustered regularly interspaced short palindromic repeat (CRISPR) systems such as Cas9.^{245,246} A major difference between the three genome editing tools is based on the fact that ZFNs and TALENs require alterations in the protein domains to target a specific gene site, whereas in the case of Cas proteins, the targeting is guided by a specific guide RNA sequence able to recognize a DNA target sequence by complementarity. Independently of the gene-editing process, after the induction of DSBs, the cell activates endogenous DNA repair pathways to fix the damage. There are two main types of repair processes, non-homologous end-joining (NHEJ) and homology directed repair (HDR).^{247–249} NHEJ is frequently associated with the presence of small insertions and deletions (indels) at the break site that can result in gene knockout. However, repair of DSBs by HDR involves the copying of DNA from a homologous donor template resulting in accurate correction of the DSB.²⁴⁹

From a chronological point of view, the first endonucleases for gene editing were zinc finger nucleases (ZFNs).²⁴² These enzymes are based on zinc finger proteins, a family of naturally occurring transcription factors, fused on an endonuclease FokI. Zinc finger domains can recognize a trinucleotide DNA sequence, whereas a set of linked zinc finger domains can recognize longer DNA sequences, providing desired on-target

Table 1 Recent siRNA- and miRNA-based brain gene silencing strategies

Delivery method	Cargo	Administration route	Target	Disease	Ref.
Viral					
rAAV1/2	siRNA	Interventricular injection	Glycogen synthase kinase-3	Alzheimer's disease	231
Lentivirus	shRNA	Intracranial	<i>Aquaporin-4</i>	Glial scar after traumatic brain injury	232
AAV5	antimiR	Intrathecal	<i>Huntingtin</i>	Huntington's disease	233
Lentivirus	shRNA	Intracranial	<i>α-synuclein</i>	Parkinson's disease	99
Lentivirus	siRNA	Intracranial	<i>BACE1</i>	Alzheimer's disease	96
Non-viral					
Gold NP	siRNA	Intravenous	<i>Bcl12l2</i>	Recurrent glioblastoma multiforme or gliosarcoma	Clinical trials-NCT03020017
Gold-iron oxide NP	antimiR	Intranasal	<i>miR-21</i>	Glioblastoma	177
Exosomes	siRNA	Intravenous	<i>BACE1</i>	Alzheimer's disease	234
PEI-capped porous silicon NP	siRNA	Intravenous	<i>MRP1</i>	Glioblastoma	235
PEI complexes	siRNA	Intravenous	<i>Claudin-5</i>	Cerebral oedema after traumatic brain injury	236
Poly(L)-lysines dendrigraft	siRNA	Intravenous	<i>Caspase-3</i>	Parkinson's disease	152
PEG-PDMAEMA nanolexes	siRNA	Intravenous	<i>BACE1</i>	Alzheimer's disease	153
PLA-hyperbranched polyglycerol NP	antimiR	Intratumoral	<i>miR-21</i>	Glioblastoma	237
PEI nanoplexes	siRNA	Intranasal	<i>Beclin-1</i>	HIV-infection brain reservoirs	238
Other					
Hydrophobic modification of siRNA	siRNA	Intrastriatal injection	<i>Huntingtin</i>	Huntington's disease	239
—	antimiR	Intravenous	miR-146a	Epilepsy	240
Aptamer-siRNA chimera	siRNA	Intraperitoneal	<i>STAT3</i>	Glioblastoma	241

AAV: adeno-associated virus; antimir: antisense oligonucleotides for miRNA inhibition; BACE1: beta-site amyloid precursor protein cleaving enzyme 1; MRP1: multidrug resistance-associated protein 1; NP: nanoparticles; PEG-PDMAEMA: PEGylated poly(2-(*N,N*-dimethylamino) ethyl methacrylate); PEI: poly(ethyleneimine); PLA: poly (lactic acid); STAT3: signal transducer and activator of transcription 3.

specificity. FokI endonuclease works as a dimer, which means that the double-strand DNA cleavage occurs only at sites of binding of two ZFNs to the opposite DNA strands.²⁴² The system is based on two ZFNs engineered to recognize different closely located nucleotide sequences within the target site and requires the simultaneous recognition and binding of both ZFNs, which naturally limits off-target effects. The potential of ZFNs as a brain gene-editing tool has been demonstrated in Huntington's disease (HD).^{250,251} HD is a dominantly inherited neurodegenerative disorder caused by expanded CAG repeats in the huntingtin (HTT) gene. The gene editing was demonstrated *in vivo*, at gene and functional levels, in an HD mouse model after stereotaxic administration in the striatum of AAV1²⁵⁰ or AAV6²⁵¹ particles encoding the ZFN. Importantly, the long-term expression of ZFNs in central neural system neurons induced significant gene repression activity for at least 6 months^{251,252} and did not induce measurable inflammation or neurodegeneration.²⁵³

TALENs were the second endonucleases to be evaluated in gene editing.^{243,254,255} A single TALE motif recognizes one nucleotide, and an array of TALEs can associate with a longer sequence. The activity of each TALE domain is restricted only to one nucleotide and does not affect the binding specificity of neighboring TALEs, making the engineering of TALENs much easier than ZFNs. Similar to ZFNs, TALE motifs are linked with FokI endonuclease, which requires dimerization for the cleavage to occur. This means that the binding of two different

TALENs at opposite strands in close vicinity to the target DNA is needed. The gene editing of potential of TALENs was demonstrated in genes associated with autism (*CACNA1C*)²⁵⁵ and dementias (*NTF3*),^{244,256} among others. TALENs have been used in zebrafish²⁵⁷ and mouse²⁵⁸ models, but their potential as an *in vivo* brain editing system remains elusive.

The discovery of CRISPR/Cas9 gene editing system in 2012 changed our paradigm of gene editing and transformed the neurosciences research area.²⁴⁵ This system is composed of an enzyme (Cas) and a guide RNA sequence that binds to a specific target sequence of DNA. The RNA complexes with the Cas9 enzyme, resulting in the formation of the Cas9 ribonucleoprotein (RNP). The most frequent enzymes are Cas9 from the bacteria strains *Streptococcus pyogenes* (SpCas9)²⁴⁵ and *Staphylococcus aureus* (SaCas9).²⁵⁹ The guide RNA (gRNA) is composed of a dual RNA sequence crRNA (CRISPR RNA) with a target for genomic DNA and tracrRNA (*trans*-activating CRISPR RNA) that binds to the enzyme. These two RNAs can also be combined into a single hybrid guide RNA (sgRNA).^{245,260} Under the guidance of gRNA, Cas9 induces precise DSBs at target locations in the genome.¹⁴ CRISPR/Cas9 system is relatively easy to prepare because only the guide RNA is different for each application, very efficient and cost-saving in comparison with other gene-editing tools. Importantly, besides the conventional genome editing of Cas9, the enzyme can act as a programmable DNA-binding module to control transcription. In this case, Cas9 nuclease is inactivated (dead

Cas9) *via* amino acid substitutions,²⁶⁰ and the resulting enzyme (dead Cas9) can be fused with transcriptional repressors such as KRAB^{261–263} or transcriptional activators such as VP64.^{262,264,265} The demonstration of the gene-editing potential of the CRISPR/Cas9 system has been demonstrated in the context of HD,^{266–269} Alzheimer's disease (AD),^{270,271} fragile X syndrome,²⁷² Parkinson's disease,^{273,274} schizophrenia,²⁷⁵ and neural stem cell gene repression,²⁷⁶ among others, both *in vitro* and *in vivo*. The *in vivo* potential of the CRISPR/Cas9 system for brain applications has been confirmed in mice,^{266,268–270,272,276} rats^{277,278} and monkeys²⁷⁹ *via* intracerebral^{266,268–272,275,280} and intrathecal²⁷⁵ administrations. Neurons,^{270,272,277,281–283} microglia,²⁷² neural stem/progenitor cells,^{276,283} and astrocytes²⁷² in animal models at embryonic,^{280,284} fetal, and adult^{270,277,284} stages have been edited. Brain cells at different locations including cerebral cortex,²⁸⁴ hippocampus,^{270,272,283,284} striatum,^{272,283,284} thalamus,²⁸⁴ hypothalamus,²⁸⁴ cerebellum,²⁸⁴ midbrain,²⁸⁴ and spinal cord²⁸⁴ have been edited, thus demonstrating the versatility of the gene-editing platform. Importantly, most of the gene-editing studies in the brain rely on the NHEJ²⁸² repair mechanism with a success as high as 60%.²⁷⁷ The selection of NHEJ rather than a HDR repair mechanism is justified by the fact that neurons are post-mitotic cells, and thus the NHEJ repair mechanism has a high efficacy. The HDR-mediated gene modification of neurons has been demonstrated in mouse adult brain albeit with limited success (as high as ~30% of the targeted neurons).²⁸⁴

4.1. Brain delivery of the CRISPR/Cas system

Despite the broad range of applications of the CRISPR/Cas9 system in the context of the brain, the efficient delivery of the CRISPR/Cas9 remains a key limiting factor. The CRISPR/Cas9 can be delivered in three different forms, including (i) DNA, (ii) messenger RNA (Cas9 mRNA), or (iii) Cas9 ribonucleoprotein (RNP) complex (Cas9:sgRNA complex).²⁸⁵ The strategies used for brain delivery of the CRISPR/Cas9 system (Table 2) can be grouped into physical delivery, viral vectors, and non-viral vectors (Fig. 3).

4.1.1 Physical delivery. The most common physical delivery methods for the delivery of the CRISPR/Cas9 system in the brain are microinjection and electroporation.^{280,283,286,287} Microinjection is a direct platform for the efficient administration of nucleic acids (*e.g.* mRNA or DNA plasmid encoding Cas9 or sgRNA) and protein complexes (Cas9 ribonucleoprotein complex) into living cells, including the pronucleus of mouse zygotes to generate knockout mouse models.²⁸⁷ The microinjection of Cas9 mRNA/sgRNA into the pronucleus showed a higher efficiency than the injection of the corresponding plasmid encoding Cas9 and gRNA or the injection of the Cas9 mRNA/sgRNA into the cytoplasm.²⁸⁸ Despite the promising results obtained so far, microinjection may induce cell damage and requires a high level of skill. Electroporation is an alternative approach for delivering the CRISPR/Cas9 system into mammalian cells. The permeability of the cell membrane increases due to pulsed high-voltage electrical cur-

rents, allowing proteins or nucleic acids to enter the cells. The electroporation methodology for the intracellular delivery of CRISPR/Cas9 system has been used in neural stem/progenitor cells,^{283,286,289} cerebellar inhibitory interneuron progenitors,²⁸⁹ and neurons^{276,280,283} both *in vitro* and *in vivo*. The advantages of electroporation include its versatility, since it has been used with different brain cell types both *in vitro* and *in vivo*, and its efficiency. The limitations of the electroporation include the absence of control in transfected cells and the fact that the methodology cannot be translated in humans.

4.1.2 Viral delivery. The viral delivery of the CRISPR/Cas9 system is the most used delivery strategy of plasmid DNA for brain applications. The viral delivery can be performed with lentivirus and adeno-associated viruses (AAVs). Lentiviruses can infect non-dividing cells, and their packaging limit is 8.5 kb, which is sufficient to package most Cas9 genes, guide RNA, and specific promoters.²⁹⁰ The vector has been used for deleting synaptic proteins in neurons²⁹¹ and transcriptional regulation,²⁶³ both *in vitro*²⁹¹ and *in vivo*,²⁶³ in this case by intracerebral administration.

AAVs are the most used vectors for *in vivo* delivery of the CRISPR/Cas9 system. Smaller Cas9 orthologs, such as spCas9 (4.2 kb) and saCas9 (3.2 kb), are the most attractive ones because they can be packaged in a single AAV vector for brain gene editing.^{21,259} The following AAV particles have been used for *in vivo* studies: AAV1,^{266,270,277,282,284,292} AAV2,^{282,293} AAV2g9,²⁷⁵ AAV8,²⁶⁴ and AAV9.^{275,281,284} These viral vectors have been used for the transfection of brain cells in dentate gyrus,²⁸² prefrontal cortex,²⁹² primary visual cortex,²⁸² olfactory bulb,^{275,284} striatum,^{266,275,284} hippocampus,^{270,275,284} and hypothalamus²⁸⁴ (Fig. 4A and B). According to some results, AAV2g9 seems to have a higher tropism to neurons than other brain cells, whereas AAV9 can transfect both neuronal and glial cells²⁷⁵ (Fig. 4C). In most studies, the viral particles were administered in the brain by intracerebral administration,^{266,275,282,292} and the introduction of knockout mutations through NHEJ^{266,269,275,282,292} and HDR.^{280,281,284} HDR-based targeted gene knock-in strategies have limitations because HDR is mainly active in dividing cells; however, some methodologies have been developed to allow DNA knock-in in both dividing and non-dividing cells *in vitro* and in the mouse brain.^{281,294} Importantly, studies have shown that AAVs can be used for the *in vivo* delivery of CRISPR/Cas9 to delete one or multiple genes in the brain.²⁸² Due to the limited capacity of AAVs to package a large amount of genetic information, vectors containing different information have been used. For example, for the brain *Mecp2* knockout, two AAVs have been used, one to express Cas9 and one to express the sgRNA and GFP.²⁸² These viruses were mixed and injected into the hippocampus where they resulted in ~80% co-transduction rate and up to 70% reduction in *Mecp2*-positive cells in the dentate gyrus. Similarly, a dual AAV-mediated strategy was successfully used to knock out the brain mutant huntingtin (HTT) gene in an HD mouse model^{268,269} as well as the APPswe mutation found in Tg2576 mice, an AD mouse model.²⁷⁰

Table 2 Viral and non-viral formulation for CRISPR/Cas9 delivery for brain gene editing

Delivery method	Cargo	Repair mechanism	Target	Efficiency	Brain disease target	Ref.
Viral						
AAV1/2	AAV-U6-sgRNA-Cre vector	NHEJ	NeuN locus/ <i>Rbfox3</i> gene	High with an indel formation near the predicted cleavage site	Brain cancer mutations	292
AAV1/2	Dual vector system: AAV-SpCas9 and AAV-SpGuide	NHEJ	<i>Mecp2</i> , <i>Dnmt1</i> , <i>Dnmt3a</i> and <i>Dnmt3b</i> genes	High	Neurodevelopmental disorders	282
AAV9 and AAV2g9	Vectors packaging two guide RNAs (gRNAs)	NHEJ	<i>MIR137</i> gene	Significant increase in mutant allele frequency	Schizophrenia	300
AAV serotypes 8 and 9 (HIFI)	Multiple vector system: AAV-Cas9, AAV-sgRNA and AAV-HDR-donor	HDR	<i>Tubb3</i> gene <i>MERTK</i> gene	Low, partial recovery of vision	Retinitis pigmentosa and Hutchinson–Gilford progeria syndrome	281 and 294
rAAV2/1	Multiple vector system: rAAV2/1-SpCas9 and rAAV-hU6sgRNA	NHEJ	<i>Mutant huntingtin</i> gene (mHTT)	High knock out levels	Huntington's disease	269 and 308
AAV	AAV-SaCas9-sgRNA	NHEJ	<i>CREB</i> gene	Lower efficiency <i>in vivo</i>	Bipolar disorders	293
AAV1 and AAV9	AAV-Cas9-gRNA	NHEJ	Mutant human APP gene (<i>APPsw</i>)	Limited gene-disruption efficiency <i>in vivo</i>	Alzheimer's disease	270
AAV8	AAV-sgRNA	Upregulate gene expression	Neurogenic transcription factors: <i>Ascl1</i> , <i>Neurog2</i> and <i>Neurod1</i>	High	Parkinson's disease	264
AAV1	AAV1-SaCas9-sgRNA	NHEJ	Huntingtin (<i>HTT</i>) gene	Moderate increases lifespan (~15%) and improves certain motor deficits in these same mice	Huntington's disease	309
AAV-SB-CRISPR	AAV-SB-sgRNA	NHEJ	<i>Pdia3</i> and <i>Mgat5</i> gene	High	Glioblastoma	310
AAV1 and AAV9	Dual vector system: AAV-SaCas9 and AAV-sgRNA	NHEJ	<i>chp</i> gene (CREB-binding protein)	High	Rubinstein–Taybi syndrome	278
CRISPRi lentivirus	All-in-one lentiviral system (dCas9-KRAB and two or three sgRNAs)	NHEJ	<i>Syt1</i> gene in the dentate gyrus (DG)	Very high	Neurodevelopmental disorder	263
lentiCRISPR	Lentiviral backbone plasmid (lentiCRISPR) encoding Cas9 and gRNA	Deletion	<i>GRIN1</i> gene	high	Neurodevelopmental disorder	291
Physical						
<i>In utero</i> electroporation	Cas9-gRNA plasmid	Knockout	<i>Grin1</i> gene	High	Neurodevelopmental disorder	311
<i>In utero</i> electroporation	Cas9-sgRNA plasmid	Deletion	<i>Nf1</i> , <i>Trp53</i> and <i>Pten</i> genes	High	Brain tumour	289
<i>In-utero</i> electroporation	Cas9-sgRNA plasmid	Knockout	<i>Satb2</i> gene	High	Neurodevelopmental disorder	312
Nucleofection	Cas9-sgRNA plasmid and donor-plasmid	HDR	<i>IL2RG</i> , <i>HBB</i> , <i>CCR5</i> genes	Very low <i>in vivo</i> correction	Krabbe disease	286
Nucleofection and Stereotaxic infusion of complexes	Cas9 ribonucleoprotein (RNP) complexes		<i>loxP-stop cassette</i>	High	NA	283
Non-viral						
Bio-reducible lipids nanoparticles	Cas9 RNP	NHEJ	<i>EGFP</i> gene <i>Cre-recombination</i>	Highly protein delivery but minimal diffusion	NA	92
CRISPR-gold nanoparticles	Cas9 RNP	Knockout	<i>loxP-stop cassette</i> and <i>mGluR5</i> gene	High	Fragile X syndrome	272
Magneto-electric nanoparticles	Cas9 RNP	Knockout	<i>HIV-1-LTR</i> gene	Significantly reduced latent infection in HIV cells	HIV-1 infection	307

Table 2 (Contd.)

Delivery method	Cargo	Repair mechanism	Target	Efficiency	Brain disease target	Ref.
Colloidal gold nanoparticles	Cas9 RNP and donor ssDNA	HDR	<i>CCR5 receptor</i>	Highest levels of HDR in CD34 + cells No-editing was observed in brain	Infectious diseases	306
NanoMEDIC (extracellular vesicles)	spCas9-sgRNA plasmids	Deletion	<i>SAMHD1</i> gene and <i>DMD (Dystrophin)</i> gene	High efficiently edit the <i>SAMHD1</i> gene in neurons	Duchenne muscular dystrophy	305

AAV: adeno-associated virus; NHEJ: nonhomologous end-joining; HDR: homology-directed repair (HDR); HIFI: homology-independent targeted integration; CRISPRi: CRISPR interference; SPH: SunTag-p65-HSF1; HD: Huntington's disease; SB: *sleeping beauty* transposon; NanoMEDIC: nanomembrane-derived extracellular vesicles for the delivery of macromolecular cargo; DMD: Duchenne muscular dystrophy; NA: not applicable.




Fig. 3 CRISPR/Cas9 delivery strategies. A variety of physical, viral and nonviral methods have been derived to achieve successful delivery across the cell membrane.

The viral delivery of the CRISPR/Cas9 system in brain cells is, in general, very efficient after intracerebral injection of the viral particles (even when two viral particles are needed to deliver the complete gene-editing formulation); however, the strategy has limitations in case the viral particles are administered by a less invasive route such as the intravenous route. Indeed, in most studies reported so far, the brain gene editing mediated by the CRISPR/Cas9 system occurred after administration of viral particles by stereotaxic injection; however, this allows the transduction of a few cubic millimetres of brain tissue, and the invasiveness of the procedure makes this delivery strategy less likely to be translated to the clinic. AAVs have been engineered for the efficient delivery of genes to the central nervous system after intravenous administration;²⁹⁵ however, the systemic administration of the virus still results in off-targets in the liver, kidney, and heart. Another limitation of the viral particles is linked to their immunogenicity and integration in the genome of the edited cell. A recent study has

shown that up to 47% of AAVs were integrated in the genome of cells edited by the CRISPR/Cas9 system.²⁹⁶ In addition, the limited gene editing in some brain regions as well as the limited efficiency of HDR repair processes may require more than one administration of the gene-editing formulation. Unfortunately, the immunogenicity associated with AAVs²⁹⁷ makes this possibility unlikely. Another issue that deserves further attention is the control of the lifespan of Cas9 transgene expression in brain cells in order to reduce its immunogenicity and off-target editing. To reduce the potential toxicity of Cas9, several studies have used self-destructing versions of Cas9, which removed Cas9 expression *via* a Cas9-specific gRNA or homologous recombination.²⁹⁸ Yet, the complexity of multiple genetic modifications may be a problem in protein activity and can potentially induce neurotoxicity. As an alternative, Cas9 has been fused with cell-cycle regulators to restrict its expression in specific cell-cycle phases.²⁹⁹




Fig. 4 Viral and non-viral delivery in gene-editing efficiency. (A) AAV-HDR for the delivery of a sgRNA and HDR donor template to insert the human influenza hemagglutinin (HA) tag in the embryonic brain. HA tag sequence is fused either to the N terminus of endogenous β -actin (which expresses ubiquitously in most of cell types) or to CaMKII α (which expresses exclusively in neurons). Confocal microscopic images of whole sagittal brain sections of Cas9 mice showing immunoreactivities for NeuN (magenta) and the HA tag (green) fused to the N terminus of endogenous β -actin (top) and CaMKII α (bottom). Reproduced with permission.⁶⁶ Copyright 2017, Elsevier. (B) Genome-editing efficiency in distinct cell types regulated by AAV-HDR administration in E10 mouse embryonic. Adapted from ref. 66. (C) Gene-editing efficiency in multiple brain cells types depends on the CRISPR delivery system. In the case of viral delivery, the AAV2g9 seems to have a higher tropism to transfect neurons than other brain cells, whereas AAV9 can transfect preferentially astrocytes, neuronal and glial cells.⁶⁶ Non-viral delivery shows higher gene editing in astrocytes and microglia (more proliferative cells), but they also can target neuro stem cells and neurons, according to ref. 272 and 283.

4.1.3 Non-viral delivery. Non-viral CRISPR/Cas delivery systems have emerged in the last 5 years as an alternative to viral or physical delivery approaches. The non-viral vectors include lipid nanoparticles,^{92,301} polyplexes,^{283,289,302,303} nanocapsules,²⁹⁴ gold nanoparticles,^{272,304} and extracellular vesicles.³⁰⁵ These formulations have been used for the delivery of both mRNA Cas9 and sgRNA,³⁰¹ Cas9 protein and sgRNA,^{272,283,302,304} or plasmid Cas9 and sgRNA²⁸⁹ to induce gene editing through NHEJ^{283,289,294} or HDR^{304,306} repair processes. However, very few formulations have been tested in the context of the brain.^{92,271,272,283,289} These non-viral vectors have been administered by the intracerebral route and used for the transfection of brain cells such as neurons,^{92,272,283,289} microglia²⁷² and neural stem/progenitor cells^{283,289} in the cortex,²⁸³ dentate gyrus,²⁷² cerebellum,²⁸⁹ striatum,²⁸³ and hippocampus.^{272,283} *In vitro* studies have shown that formulations were taken up by brain cells by caveolae/raft-dependent endocytosis.³⁰⁴ In general, the *in vivo* gene-editing efficiency varied between 15%²⁷² and 70%²⁷¹ (Fig. 4C).

The principles used for the preparation of the non-viral formulations took into consideration the selection of the CRISPR/Cas system components and strategies to facilitate the cellular internalization of the formulation (Fig. 5). First, apart from two studies,^{289,301} Cas proteins have been used as gene-editing enzymes. In general, the complexation of the sgRNA to Cas proteins has been made before the preparation of the nanoparticle. Second, the formulations have been prepared with components that enhanced (i) cellular internalization, (ii)

endolysosomal compartment escape, and (iii) nuclear localization. To increase cellular uptake, the CRISPR/Cas9 system components were encapsulated or complexed with polycationic agents such as poly(ethyleneimine) (PEI),²⁸⁹ lipofectamine,²⁸³ or a cationic endosomal disruptive polymer PAsp (DET).^{272,304} To increase nuclear targeting, the Cas9 protein has been modified with four copies of SV40-NLS,²⁸³ whereas bio-reducible lipid nanoparticles have been used to increase endolysosomal escape.⁹² Third, some formulations, particularly those for HDR repair processes,²⁷² have used the core of the nanoparticle to immobilize the repair template by hybridization with complementary oligonucleotides immobilized in the surface of the nanoparticle.

In general, non-viral formulations compare favourably to viral formulations concerning the absence of its integration in the cellular genome, packaging capacity, and control in spatio-temporal release of the CRISPR/Cas cargo (Fig. 3). An important safety aspect related to brain gene editing is related to the immune response to the Cas9 RNP. Some studies indicate that Cas9RNP NPs delivered in the mouse brain did not activate microglia, the mainstay of the immune cells of the central nervous system.²⁸³ Therefore, the formulations seem to be safe; however, further studies are necessary to investigate this issue in greater detail (Fig. 5). In addition, although some formulations tested so far in the context of the brain showed a higher preference for neurons than for astrocytes,²⁸³ the control of gene editing in specific brain cell populations remains to be demonstrated. Another issue that remains to be investigated is whether




Fig. 5 CRISPR–Cas9 ribonucleoprotein complex challenges related to improving gene-editing efficiency (left) as well as tools and biomaterials for designing more efficient delivery systems in the future (right).

the non-viral formulations can be administered by the intravenous route and accumulate in the brain. This strategy could simplify enormously the application of gene-editing formulations for brain applications. Recently, a magnetically guided non-invasive delivery of nanoparticles containing CRISPR/Cas9 vector was demonstrated that can cross the blood–brain barrier (BBB) to inhibit latent HIV-1 infection in microglial cells.³⁰⁷

4.1.4 Outlook. In the last decade, significant progress has been made in the delivery of gene therapies to the brain. We now have a better understanding of the properties of the delivery vehicles (viral and non-viral) to target specific brain cells,¹⁴² knowledge about strategies to overcome the blood–brain barrier and reach specific brain sites,^{313,314} tools to reproduce *in vitro* human BBB models and test formulation permeability,^{315,316} and advanced formulations to cross the BBB.^{317,318} As a consequence of this progress, several clinical

trials (<https://clinicaltrials.gov/>) have been carried out on brain gene therapies for the treatment of PD (*e.g.* for the expression of GDNF in the brain) (NCT04167540),³¹⁹ AD (*e.g.* for the expression of active telomerase, apolipoprotein E2) (NCT03634007; NCT04133454),^{320,321} gangliosidosis (*e.g.* by the delivery of a functional copy of the GLB1 gene to the CNS) (NCT03952637),³²² and metachromatic leukodystrophy (NCT03725670).³²³ Most of these strategies involve the expression of proteins to replace those missing or mutated (and thus not active).

Presently, brain gene-editing approaches have not reached the clinical trial stage. However, gene-editing approaches outside the brain are now in clinical trials. For example, a recent study has demonstrated the safety and feasibility of gene-editing human T lymphocytes in cancer patients in order to improve their antitumor activity.³²⁴ In coming years, clinical

trials in brain gene editing are expected. CRISPR/Cas9-mediated genome editing will provide important advances in novel therapeutic targets or in multiple targets. Non-viral systems have great potential for packaging and delivering large genetic payloads and reducing the risk of insertional errors that can occur with viral gene delivery. Gene-therapy formulations for the silencing of specific brain genes may also find applications in the context of certain neurodegenerative diseases. For example, Patisiran, a lipid-siRNA formulation developed by Alnylam® Pharmaceuticals (<https://www.alnylam.com/>), has been approved in the US and Europe to target transthyretin-mediated amyloidosis.³²⁵

A limiting problem in brain gene therapy is brain delivery. This limitation is due to the high complexity of the brain and the impermeability of the blood-brain barrier. Formulations have been developed that are able to cross the BBB efficiently and accumulate in the brain parenchyma.^{317,318} In addition, the transient opening of the BBB by the use of focused ultrasound may further enhance the accumulation of formulations in the brain.³¹⁴ These tools should now be investigated for the delivery of gene therapies in the brain.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

J. C. acknowledges the European Research Council Starting Grant (ERC-StG-2019-848325).

References

- 1 S. Jenks, *JNCI, J. Natl. Cancer Inst.*, 2000, **92**, 98–100.
- 2 J. L. Fox, *Nat. Biotechnol.*, 2000, **18**, 1136–1136.
- 3 S. W. J. McPhee, C. G. Janson, C. Li, R. J. Samulski, A. S. Camp, J. Francis, D. Shera, L. Lioutermann, M. Feely, A. Freese and P. Leone, *J. Gene Med.*, 2006, **8**, 577–588.
- 4 W. J. Marks, J. L. Ostrem, L. Verhagen, P. A. Starr, P. S. Larson, R. A. E. Bakay, R. Taylor, D. A. Cahn-Weiner, A. J. Stoessl, C. W. Olanow and R. T. Bartus, *Lancet Neurol.*, 2008, **7**, 400–408.
- 5 M. A. Kotterman, T. W. Chalberg and D. V. Schaffer, *Annu. Rev. Biomed. Eng.*, 2015, **17**, 63–89.
- 6 A. Jagannath and M. Wood, *Briefings Funct. Genomics*, 2007, **6**, 40–49.
- 7 R. K. M. Leung and P. A. Whittaker, *Pharmacol. Ther.*, 2005, **107**, 222–239.
- 8 J. K. W. Lam, M. Y. T. Chow, Y. Zhang and S. W. S. Leung, *Mol. Ther.–Nucleic Acids*, 2015, **4**, e252.
- 9 A. G. Bader, D. Brown and M. Winkler, *Cancer Res.*, 2010, **70**, 7027.
- 10 D. B. T. Cox, R. J. Platt and F. Zhang, *Nat. Med.*, 2015, **21**, 121–131.
- 11 F. D. Urnov, E. J. Rebar, M. C. Holmes, H. S. Zhang and P. D. Gregory, *Nat. Rev. Genet.*, 2010, **11**, 636–646.
- 12 A. J. Bogdanove and D. F. Voytas, *Science*, 2011, **333**, 1843–1846.
- 13 A. M. Scharenberg, P. Duchateau and J. Smith, *Curr. Gene Ther.*, 2013, **13**, 291–303.
- 14 P. D. Hsu, E. S. Lander and F. Zhang, *Cell*, 2014, **157**, 1262–1278.
- 15 V. J. McCurdy, H. E. Rockwell, J. R. Arthur, A. M. Bradbury, A. K. Johnson, A. N. Randle, B. L. Brunson, M. Hwang, H. L. Gray-Edwards, N. E. Morrison, J. A. Johnson, H. J. Baker, N. R. Cox, T. N. Seyfried, M. Sena-Esteves and D. R. Martin, *Gene Ther.*, 2015, **22**, 181–189.
- 16 S. Ramaswamy, J. L. McBride, I. Han, E. M. Berry-Kravis, L. Zhou, C. D. Herzog, M. Gasmi, R. T. Bartus and J. H. Kordower, *Neurobiol. Dis.*, 2009, **34**, 40–50.
- 17 S. R. Murphy, C. C. Y. Chang, G. Dogbevia, E. Y. Bryleva, Z. Bowen, M. T. Hasan and T. Y. Chang, *Mol. Ther.*, 2013, **21**, 1497–1506.
- 18 D. Saha, R. L. Martuza and S. D. Rabkin, *Immunotherapy*, 2018, **10**, 779–786.
- 19 C. Saraiva, C. Praça, R. Ferreira, T. Santos, L. Ferreira and L. Bernardino, *J. Controlled Release*, 2016, **235**, 34–47.
- 20 S. Ingusci, G. Verlengia, M. Soukupova, S. Zucchini and M. Simonato, *Front. Pharmacol.*, 2019, **10**, 724.
- 21 B. E. Deverman, B. M. Ravina, K. S. Bankiewicz, S. M. Paul and D. W. Sah, *Nat. Rev. Drug Discovery*, 2018, **17**, 641–659.
- 22 F. Schlachetzki, Y. Zhang, R. J. Boado and W. M. Pardridge, *Neurology*, 2004, **62**, 1275–1281.
- 23 M. Simonato, J. Bennett, N. M. Boulis, M. G. Castro, D. J. Fink, W. F. Goins, S. J. Gray, P. R. Lowenstein, L. H. Vandenberghe and T. J. Wilson, *Nat. Rev. Neurol.*, 2013, **9**, 277–291.
- 24 W. M. Pardridge, *Neuron*, 2002, **36**, 555–558.
- 25 M.-L. Rogers and R. A. Rush, *J. Controlled Release*, 2012, **157**, 183–189.
- 26 T. B. Lentz, S. J. Gray and R. J. Samulski, *Neurobiol. Dis.*, 2012, **48**, 179–188.
- 27 C. E. Thomas, A. Ehrhardt and M. A. Kay, *Nat. Rev. Genet.*, 2003, **4**, 346–358.
- 28 M. A. Kay, J. C. Glorioso and L. Naldini, *Nat. Med.*, 2001, **7**, 33–40.
- 29 B. L. Davidson and X. O. Breakefield, *Nat. Rev. Neurosci.*, 2003, **4**, 353–364.
- 30 S. R. Choudhury, E. Hudry, C. A. Maguire, M. Sena-Esteves, X. O. Breakefield and P. Grandi, *Neuropharmacology*, 2017, **120**, 63–80.
- 31 W. T. J. M. C. Hermens and J. Verhaagen, *Prog. Neurobiol.*, 1998, **55**, 399–432.
- 32 M. Giacca and S. Zacchigna, *J. Controlled Release*, 2012, **161**, 377–388.
- 33 M. Hocquemiller, L. Giersch, M. Audrain, S. Parker and N. Cartier, *Hum. Gene Ther.*, 2016, **27**, 478–496.
- 34 H. Fu and D. M. McCarty, *Curr. Opin. Virol.*, 2016, **21**, 87–92.

- 35 L. Costantini, J. Bakowska, X. Breakefield and O. Isacson, *Gene Ther.*, 2000, **7**, 93–109.
- 36 K. Lundstrom, *Diseases*, 2018, **6**, 42.
- 37 X. Danthinne and M. Imperiale, *Gene Ther.*, 2000, **7**, 1707–1714.
- 38 R. Alba, A. Bosch and M. Chillon, *Gene Ther.*, 2005, **12**, S18–S27.
- 39 M. Candolfi, J. F. Curtin, W.-D. Xiong, K. M. Kroeger, C. Liu, A. Rentsendorj, H. Agadjanian, L. Medina-Kauwe, D. Palmer and P. Ng, *Mol. Ther.*, 2006, **14**, 371–381.
- 40 M. Candolfi, G. E. Pluhar, K. Kroeger, M. Puntel, J. Curtin, C. Barcia, A. G. Muhammad, W. Xiong, C. Liu and S. Mondkar, *Neuro-Oncology*, 2007, **9**, 245–258.
- 41 A. K. M. G. Muhammad, M. Puntel, M. Candolfi, A. Salem, K. Yagiz, C. Farrokhi, K. M. Kroeger, W. Xiong, J. F. Curtin, C. Liu, K. Lawrence, N. S. Bondale, J. Lerner, G. J. Baker, D. Foulad, R. N. Pechnick, D. Palmer, P. Ng, P. R. Lowenstein and M. G. Castro, *Clin. Pharmacol. Ther.*, 2010, **88**, 204–213.
- 42 *Human Gene Therapy Methods*, 2012, vol. 23, pp. 271–284, ISSN: 1946–6536, <https://www.liebertpub.com/toc/hgtb/23/4>.
- 43 M. J. Bellini, C. B. Hereñú, R. G. Goya and L. M. Garcia-Segura, *J. Neuroinflammation*, 2011, **8**, 21.
- 44 X.-R. Zheng, S.-S. Zhang, Y.-J. Yang, F. Yin, X. Wang, L. Zhong and X.-H. Yu, *Brain Res. Bull.*, 2010, **81**, 372–377.
- 45 A. Alonso, E. Reinz, B. Leuchs, J. Kleinschmidt, M. Fatar, B. Geers, I. Lentacker, M. G. Hennerici, S. C. de Smedt and S. Meairs, *Mol. Ther.–Nucleic Acids*, 2013, **2**, e73.
- 46 M. J. Benskey, N. C. Kuhn, J. J. Galligan, J. Garcia, S. E. Boye, W. W. Hauswirth, C. Mueller, S. L. Boye and F. P. Manfredsson, *Mol. Ther.*, 2015, **23**, 488–500.
- 47 D. Wang, L. Zhong, M. Li, J. Li, K. Tran, L. Ren, R. He, J. Xie, R. P. Moser and C. Fraser, *Mol. Ther.–Methods Clin. Dev.*, 2018, **11**, 65–72.
- 48 N. Nayerossadat, T. Maedeh and P. A. Ali, *Adv. Biomed. Res.*, 2012, **1**, 1–11.
- 49 M. A. Kotterman and D. V. Schaffer, *Nat. Rev. Genet.*, 2014, **15**, 445–451.
- 50 L. Shen, J. Miao, F. Yuan, Y. Zhao, Y. Tang, Y. Wang and G. Yang, *Gene Ther.*, 2013, **20**, 93–101.
- 51 F. Shen, R. Kuo, M. Milon-Camus, Z. Han, L. Jiang, W. L. Young and H. Su, *Stroke*, 2013, **44**, 252–254.
- 52 D. Doycheva, N. Xu, J. Tang and J. Zhang, *J. Neuroinflammation*, 2019, **16**, 174.
- 53 M. S. Rafii, M. H. Tuszyński, R. G. Thomas, D. Barba, J. B. Brewer, R. A. Rissman, J. Siffert, P. S. Aisen and f. t. A.-N. S. Team, *JAMA Neurol.*, 2018, **75**, 834–841.
- 54 Y.-C. Chen, N.-X. Ma, Z.-F. Pei, Z. Wu, F. H. Do-Monte, S. Keefe, E. Yellin, M. S. Chen, J.-C. Yin, G. Lee, A. Minier-Toribio, Y. Hu, Y.-T. Bai, K. Lee, G. J. Quirk and G. Chen, *Mol. Ther.*, 2020, **28**, 217–234.
- 55 M. S. Rafii, T. L. Baumann, R. A. Bakay, J. M. Ostrove, J. Siffert, A. S. Fleisher, C. D. Herzog, D. Barba, M. Pay and D. P. Salmon, *Alzheimer's Dementia*, 2014, **10**, 571–581.
- 56 T. R. Doeppner, M. Doehring, E. Bretschneider, A. Zechariah, B. Kaltwasser, B. Müller, J. C. Koch, M. Bähr, D. M. Hermann and U. Michel, *Acta Neuropathol.*, 2013, **126**, 251–265.
- 57 D. Bhare, K. Tamura, H. Wakimoto, S. H. Choi, B. Purow, J. Debatisse and K. Shah, *Neuro-Oncology*, 2017, **20**, 215–224.
- 58 R. Martier, M. Sogorb-Gonzalez, J. Stricker-Shaver, J. Hübener-Schmid, S. Keskin, J. Klima, L. J. Toonen, S. Juhas, J. Juhasova, Z. Ellederova, J. Motlik, E. Haas, S. van Deventer, P. Konstantinova, H. P. Nguyen and M. M. Evers, *Mol. Ther.–Methods Clin. Dev.*, 2019, **15**, 343–358.
- 59 J. Miniarikova, V. Zimmer, R. Martier, C. C. Brouwers, C. Pythoud, K. Richetin, M. Rey, J. Lubelski, M. M. Evers and S. J. van Deventer, *Gene Ther.*, 2017, **24**, 630–639.
- 60 D. Bhare, N. Arghiani, E. R. Lechtich, Y. Yao, S. Alsaab, F. Bei, M. M. Matin and K. Shah, *Sci. Rep.*, 2020, **10**, 1779.
- 61 I. Zafir-Lavie, S. Sherbo, H. Goltsman, F. Badinter, E. Yeini, P. Ofek, R. Miari, O. Tal, A. Liran and T. Shatil, *J. Controlled Release*, 2018, **291**, 80–89.
- 62 M. Shimada, S. Abe, T. Takahashi, K. Shiozaki, M. Okuda, H. Mizukami, D. M. Klinman, K. Ozawa and K. Okuda, *PLoS One*, 2013, **8**, e57606.
- 63 F. Moda, C. Vimercati, I. Campagnani, M. Ruggerone, G. Giaccone, M. Morbin, L. Zentilin, M. Giacca, I. Zucca and G. Legname, *Prion*, 2012, **6**, 383–390.
- 64 S. Bäck, J. Necarsulmer, L. R. Whitaker, L. M. Coke, P. Koivula, E. J. Heathward, L. V. Fortunato, Y. Zhang, C. G. Yeh, H. A. Baldwin, M. D. Spencer, C. A. Mejias-Aponte, J. Pickel, A. F. Hoffman, C. E. Spivak, C. R. Lupica, S. M. Underhill, S. G. Amara, A. Domanskyi, J. E. Anttila, M. Airavaara, B. T. Hope, F. K. Hamra, C. T. Richie and B. K. Harvey, *Neuron*, 2019, **102**, 105–119.
- 65 J.-Z. Wang, P. Wu, Z.-M. Shi, Y.-L. Xu and Z.-J. Liu, *Brain Dev.*, 2017, **39**, 547–556.
- 66 J. Nishiyama, T. Mikuni and R. Yasuda, *Neuron*, 2017, **96**, 755–768.
- 67 B. György, C. Lööv, M. P. Zaborowski, S. Takeda, B. P. Kleinstiver, C. Commings, K. Kastanenka, D. Mu, A. Volak, V. Giedraitis, L. Lannfelt, C. A. Maguire, J. K. Joung, B. T. Hyman, X. O. Breakefield and M. Ingelsson, *Mol. Ther.–Nucleic Acids*, 2018, **11**, 429–440.
- 68 C. M. Fuentes and D. V. Schaffer, *Curr. Opin. Biomed. Eng.*, 2018, **7**, 33–41.
- 69 J. Hartmann, F. B. Thalheimer, F. Höpfner, T. Kerzel, K. Khodosevich, D. García-González, H. Monyer, I. Diester, H. Büning, J. E. Carette, P. Fries and C. J. Buchholz, *Mol. Ther.–Methods Clin. Dev.*, 2019, **14**, 252–260.
- 70 P.-H. Hsu, K.-C. Wei, C.-Y. Huang, C.-J. Wen, T.-C. Yen, C.-L. Liu, Y.-T. Lin, J.-C. Chen, C.-R. Shen and H.-L. Liu, *PLoS One*, 2013, **8**, e57682.
- 71 J. M. Mudannayake, A. Mouravlev, D. M. Fong and D. Young, *Mol. Ther.–Methods Clin. Dev.*, 2016, **3**, 16075.
- 72 S. Powell, N. Khan, C. Parker, R. Samulski, G. Matsushima, S. Gray and T. McCown, *Gene Ther.*, 2016, **23**, 807–814.

- 73 G. von Jonquieres, D. Fröhlich, C. B. Klugmann, X. Wen, A. E. Harasta, R. Ramkumar, Z. H. Spencer, G. D. Housley and M. Klugmann, *Front. Mol. Neurosci.*, 2016, **9**, 13.
- 74 B. Caffery, J. S. Lee and A. A. Alexander-Bryant, *Nanomaterials*, 2019, **9**, 105.
- 75 N. Nayerossadat, T. Maedeh and P. A. Ali, *Adv. Biomed. Res.*, 2012, **1**, 27–27.
- 76 J. Connolly, *Gene Ther.*, 2002, **9**, 1730–1734.
- 77 Z. Lai and R. O. Brady, *J. Neurosci. Res.*, 2002, **67**, 363–371.
- 78 J. Jakobsson, C. Ericson, M. Jansson, E. Björk and C. Lundberg, *J. Neurosci. Res.*, 2003, **73**, 876–885.
- 79 J. Jakobsson and C. Lundberg, *Mol. Ther.*, 2006, **13**, 484–493.
- 80 D. Blessing and N. Déglon, *Curr. Opin. Virol.*, 2016, **21**, 61–66.
- 81 J. Jakobsson, T. T. Nielsen, K. Staflin, B. Georgievskia and C. Lundberg, *Gene Ther.*, 2006, **13**, 966–973.
- 82 A. Colin, M. Faideau, N. Dufour, G. Auregan, R. Hassig, T. Andrieu, E. Brouillet, P. Hantraye, G. Bonvento and N. Déglon, *Glia*, 2009, **57**, 667–679.
- 83 M. Humbel, M. Ramosaj, V. Zimmer, S. Regio, L. Aeby, S. Moser, A. Boizot, M. Sipion, M. Rey and N. Déglon, *Gene Ther.*, 2020, 1–14.
- 84 R. Schlimgen, J. Howard, D. Wooley, M. Thompson, L. R. Baden, O. O. Yang, D. C. Christiani, G. Mostoslavsky, D. V. Diamond, E. G. Duane, K. Byers, T. Winters, J. A. Gelfand, G. Fujimoto, T. W. Hudson and J. M. Vyas, *J. Occup. Environ. Med.*, 2016, **58**, 1159–1166.
- 85 H. Miyoshi, U. Blömer, M. Takahashi, F. H. Gage and I. M. Verma, *J. Virol.*, 1998, **72**, 8150–8157.
- 86 M. C. Milone and U. O'Doherty, *Leukemia*, 2018, **32**, 1529–1541.
- 87 M. Åkerblom, R. Sachdeva, L. Quintino, E. E. Wettergren, K. Z. Chapman, G. Manfre, O. Lindvall, C. Lundberg and J. Jakobsson, *Nat. Commun.*, 2013, **4**, 1–8.
- 88 L. Zeng, X. He, Y. Wang, Y. Tang, C. Zheng, H. Cai, J. Liu, Y. Fu and G. Yang, *Gene Ther.*, 2014, **21**, 37–43.
- 89 M. K. Sayeg, B. H. Weinberg, S. S. Cha, M. Goodloe, W. W. Wong and X. Han, *ACS Synth. Biol.*, 2015, **4**, 788–795.
- 90 L. Chen, K. Zhang, Z. Shi, A. Zhang, Z. Jia, G. Wang, P. Pu, C. Kang and L. Han, *Oncol. Rep.*, 2014, **31**, 1573–1580.
- 91 M. Ghasemi-Kasman, H. Baharvand and M. Javan, *Biomed. Pharmacother.*, 2017, **96**, 1222–1229.
- 92 C.-D. Liu, Q. Wang, D.-K. Zong, S.-C. Pei, Y. Yan, M.-L. Yan, L.-L. Sun, Y.-Y. Hao, M. Mao, W.-J. Xing, H. Ren and J. Ai, *Neurobiol. Aging*, 2016, **45**, 76–87.
- 93 Y. Zhang, B. Han, Y. He, D. Li, X. Ma, Q. Liu and J. Hao, *Neurochem. Int.*, 2017, **107**, 182–190.
- 94 J. Zhang, Y. Wang, P. Zhu, X. Wang, M. Lv and H. Feng, *J. Neurol. Sci.*, 2012, **320**, 6–11.
- 95 P. Kumar, H. Wu, J. L. McBride, K.-E. Jung, M. H. Kim, B. L. Davidson, S. K. Lee, P. Shankar and N. Manjunath, *Nature*, 2007, **448**, 39–43.
- 96 O. Singer, R. A. Marr, E. Rockenstein, L. Crews, N. G. Coufal, F. H. Gage, I. M. Verma and E. Masliah, *Nat. Neurosci.*, 2005, **8**, 1343–1349.
- 97 J.-L. Dreyer, *Mol. Biotechnol.*, 2011, **47**, 169–187.
- 98 P. Zhao, C. Wang, Z. Fu, Y. You, Y. Cheng, X. Lu, A. Lu, N. Liu, P. Pu and C. Kang, *Int. J. Oncol.*, 2007, **31**, 361–368.
- 99 M. K. Sapru, J. W. Yates, S. Hogan, L. Jiang, J. Halter and M. C. Bohn, *Exp. Neurol.*, 2006, **198**, 382–390.
- 100 C. Van den Haute, K. Eggermont, B. Nuttin, Z. Debyser and V. Baekelandt, *Hum. Gene Ther.*, 2003, **14**, 1799–1807.
- 101 T. H. Hutson, E. Foster, J. M. Dawes, R. Hindges, R. J. Yáñez-Muñoz and L. D. Moon, *J. Gene Med.*, 2012, **14**, 299–315.
- 102 H.-F. Wu, J.-S. Cen, Q. Zhong, L. Chen, J. Wang, D. Y. B. Deng and Y. Wan, *Biomaterials*, 2013, **34**, 1686–1700.
- 103 Q. Hu, C. Chen, N. H. Khatibi, L. Li, L. Yang, K. Wang, J. Han, W. Duan, J. H. Zhang and C. Zhou, *Brain Res.*, 2011, **1367**, 347–359.
- 104 B. Kantor, R. M. Bailey, K. Wimberly, S. N. Kalburgi and S. J. Gray, in *Advances in genetics*, Elsevier, 2014, vol. 87, pp. 125–197.
- 105 S. De Silva and W. J. Bowers, *Viruses*, 2009, **1**, 594–629.
- 106 K. A. Cassady and J. N. Parker, *Open Virol. J.*, 2010, **4**, 103.
- 107 P. Marconi, D. Krisky, T. Oligino, P. L. Poliani, R. Ramakrishnan, W. F. Goins, D. J. Fink and J. C. Glorioso, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 11319.
- 108 S. Artusi, Y. Miyagawa, W. F. Goins, J. B. Cohen and J. C. Glorioso, *Diseases*, 2018, **6**, 74.
- 109 B. K. Berges, J. H. Wolfe and N. W. Fraser, *Mol. Ther.*, 2007, **15**, 20–29.
- 110 G. Zhang, G. Jin, X. Nie, R. Mi, G. Zhu, W. Jia and F. Liu, *PLoS One*, 2014, **9**, e95872.
- 111 W. Zhang, G. Fulci, H. Wakimoto, T. A. Cheema, J. S. Buhrman, D. S. Jeyaretna, A. O. S. Rachamimov, S. D. Rabkin and R. L. Martuza, *Neoplasia*, 2013, **15**, 591–599.
- 112 D. M. Patel, P. M. Foreman, L. B. Nabors, K. O. Riley, G. Y. Gillespie and J. M. Markert, *Hum. Gene Ther.: Clin. Dev.*, 2016, **27**, 69–78.
- 113 J. C. Corona, A. Gimenez-Cassina, F. Lim and J. Díaz-Nido, *J. Neurosci. Res.*, 2010, **88**, 1943–1950.
- 114 H. Uchida, M. Marzulli, K. Nakano, W. F. Goins, J. Chan, C.-S. Hong, L. Mazzacurati, J. Y. Yoo, A. Haseley, H. Nakashima, H. Baek, H. Kwon, I. Kumagai, M. Kuroki, B. Kaur, E. A. Chiocca, P. Grandi, J. B. Cohen and J. C. Glorioso, *Mol. Ther.*, 2013, **21**, 561–569.
- 115 C. Passaro, Q. Alayo, I. DeLaura, J. McNulty, K. Grauwet, H. Ito, V. Bhaskaran, M. Mineo, S. E. Lawler and K. Shah, *Clin. Cancer Res.*, 2019, **25**, 290–299.
- 116 H. Decker, S. Jürgensen, M. F. Adrover, J. Brito-Moreira, T. R. Bomfim, W. L. Klein, A. L. Epstein, F. G. De Felice, D. Jerusalinsky and S. T. Ferreira, *J. Neurochem.*, 2010, **115**, 1520–1529.
- 117 S. T. Lim, M. Airavaara and B. K. Harvey, *Pharmacol. Res.*, 2010, **61**, 14–26.
- 118 H. Yin, R. L. Kanasty, A. A. Eltoukhy, A. J. Vegas, J. R. Dorkin and D. G. Anderson, *Nat. Rev. Genet.*, 2014, **15**, 541–555.

- 119 D. W. Pack, A. S. Hoffman, S. Pun and P. S. Stayton, *Nat. Rev. Drug Discovery*, 2005, **4**, 581–593.
- 120 Y. Zhou, Z. Peng, E. S. Seven and R. M. Leblanc, *J. Controlled Release*, 2018, **270**, 290–303.
- 121 R. D. Jayant, D. Sosa, A. Kaushik, V. Atluri, A. Vashist, A. Tomitaka and M. Nair, *Expert Opin. Drug Delivery*, 2016, **13**, 1433–1445.
- 122 M. Ramamoorth and A. Narvekar, *J. Clin. Diagn. Res.*, 2015, **9**, GE01–GE06.
- 123 S. Wohlfart, S. Gelperina and J. Kreuter, *J. Controlled Release*, 2012, **161**, 264–273.
- 124 T.-T. Zhang, W. Li, G. Meng, P. Wang and W. Liao, *Biomater. Sci.*, 2016, **4**, 219–229.
- 125 X. Wei, X. Chen, M. Ying and W. Lu, *Acta Pharm. Sin. B*, 2014, **4**, 193–201.
- 126 H. Gao, *Acta Pharm. Sin. B*, 2016, **6**, 268–286.
- 127 K. F. Timbie, B. P. Mead and R. J. Price, *J. Controlled Release*, 2015, **219**, 61–75.
- 128 J. M. Bergen, I.-K. Park, P. J. Horner and S. H. Pun, *Pharm. Res.*, 2008, **25**, 983–998.
- 129 A. E. Aly and B. L. Waszczak, *Expert Opin. Drug Delivery*, 2015, **12**, 1923–1941.
- 130 J. B. Wolinsky, Y. L. Colson and M. W. Grinstaff, *J. Controlled Release*, 2012, **159**, 14–26.
- 131 D. S. Hersh, A. S. Wadajkar, N. B. Roberts, J. G. Perez, N. P. Connolly, V. Frenkel, J. A. Winkles, G. F. Woodworth and A. J. Kim, *Curr. Pharm. Des.*, 2016, **22**, 1177–1193.
- 132 D. B. Vieira and L. F. Gamarra, *Int. J. Nanomed.*, 2016, **11**, 5381.
- 133 M. Agrawal, Ajazuddin, D. K. Tripathi, S. Saraf, S. Saraf, S. G. Antimisariar, S. Mourtas, M. Hammarlund-Udenaes and A. Alexander, *J. Controlled Release*, 2017, **260**, 61–77.
- 134 E. Quagliarini, R. Di Santo, S. Palchetti, G. Ferri, F. Cardarelli, D. Pozzi and G. Caracciolo, *Pharmaceutics*, 2020, **12**, 1–13.
- 135 L. Wasungu and D. Hoekstra, *J. Controlled Release*, 2006, **116**, 255–264.
- 136 D. B. Vieira and L. F. Gamarra, *Int. J. Nanomed.*, 2016, **11**, 5381–5414.
- 137 X. Cheng and R. J. Lee, *Adv. Drug Delivery Rev.*, 2016, **99**, 129–137.
- 138 G. Erel-Akbaba, L. A. Carvalho, T. Tian, M. Zinter, H. Akbaba, P. J. Obeid, E. A. Chiocca, R. Weissleder, A. G. Kantarci and B. A. Tannous, *ACS Nano*, 2019, **13**, 4028–4040.
- 139 J. Jin, K. H. Bae, H. Yang, S. J. Lee, H. Kim, Y. Kim, K. M. Joo, S. W. Seo, T. G. Park and D.-H. Nam, *Bioconjugate Chem.*, 2011, **22**, 2568–2572.
- 140 N. K. Yaghi, J. Wei, Y. Hashimoto, L.-Y. Kong, K. Gabrusiewicz, E. K. Nduom, X. Ling, N. Huang, S. Zhou and B. C. P. Kerrigan, *Neuro-Oncology*, 2017, **19**, 372–382.
- 141 Z. R. Cohen, S. Ramishetti, N. Peshes-Yaloz, M. Goldsmith, A. Wohl, Z. Zibly and D. Peer, *ACS Nano*, 2015, **9**, 1581–1591.
- 142 D. Yu, O. F. Khan, M. L. Suvà, B. Dong, W. K. Panek, T. Xiao, M. Wu, Y. Han, A. U. Ahmed and I. V. Balyasnikova, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, E6147–E6156.
- 143 P. M. Costa, A. L. Cardoso, C. Custódia, P. Cunha, L. P. de Almeida and M. C. P. de Lima, *J. Controlled Release*, 2015, **207**, 31–39.
- 144 T. Tsujiuchi, A. Natsume, K. Motomura, G. Kondo, M. Ranjit, R. Hachisu, I. Sugimura, S. Tomita, I. Takehara, M. Woolley, N. U. Barua, S. S. Gill, A. S. Bienemann, Y. Yamashita, S. Toyokuni and T. Wakabayashi, *Am. J. Transl. Res.*, 2014, **6**, 169–178.
- 145 H. Lv, S. Zhang, B. Wang, S. Cui and J. Yan, *J. Controlled Release*, 2006, **114**, 100–109.
- 146 T. Merdan, J. Kopeček and T. Kissel, *Adv. Drug Delivery Rev.*, 2002, **54**, 715–758.
- 147 M. A. Mintzer and E. E. Simanek, *Chem. Rev.*, 2009, **109**, 259–302.
- 148 Z. Liu, Z. Zhang, C. Zhou and Y. Jiao, *Prog. Polym. Sci.*, 2010, **35**, 1144–1162.
- 149 I.-K. Park, K. Singha, R. B. Arote, Y.-J. Choi, W. J. Kim and C.-S. Cho, *Macromol. Rapid Commun.*, 2010, **31**, 1122–1133.
- 150 S. An, Y. Kuang, T. Shen, J. Li, H. Ma, Y. Guo, X. He and C. Jiang, *Biomaterials*, 2013, **34**, 8949–8959.
- 151 J. Shen, Z. Zhao, W. Shang, C. Liu, B. Zhang, Z. Xu and H. Cai, *Artif. Cells, Nanomed., Biotechnol.*, 2018, **46**, 894–903.
- 152 Y. Liu, Y. Guo, S. An, Y. Kuang, X. He, H. Ma, J. Li, J. Lv, N. Zhang and C. Jiang, *PLoS One*, 2013, **8**, e62905.
- 153 P. Wang, X. Zheng, Q. Guo, P. Yang, X. Pang, K. Qian, W. Lu, Q. Zhang and X. Jiang, *J. Controlled Release*, 2018, **279**, 220–233.
- 154 T. Yin, P. Wang, J. Li, R. Zheng, B. Zheng, D. Cheng, R. Li, J. Lai and X. Shuai, *Biomaterials*, 2013, **34**, 4532–4543.
- 155 C. Zhang, Z. Gu, L. Shen, X. Liu and H. Lin, *Curr. Pharm. Biotechnol.*, 2017, **18**, 1124–1131.
- 156 M. Van Woensel, T. Mathivet, N. Wauthoz, R. Rosière, A. D. Garg, P. Agostinis, V. Mathieu, R. Kiss, F. Lefranc and L. Boon, *Sci. Rep.*, 2017, **7**, 1–14.
- 157 B. M. Godinho, J. R. Ogier, R. Darcy, C. M. O'Driscoll and J. F. Cryan, *Mol. Pharm.*, 2013, **10**, 640–649.
- 158 S. Son, J. Jang, H. Youn, S. Lee, D. Lee, Y.-S. Lee, J. M. Jeong, W. J. Kim and D. S. Lee, *Biomaterials*, 2011, **32**, 4968–4975.
- 159 C. Helmschrodt, S. Höbel, S. Schöninger, A. Bauer, J. Bonicelli, M. Gringmuth, S. A. Fietz, A. Aigner, A. Richter and F. Richter, *Mol. Ther.–Nucleic Acids*, 2017, **9**, 57–68.
- 160 C.-Q. Mao, J.-Z. Du, T.-M. Sun, Y.-D. Yao, P.-Z. Zhang, E.-W. Song and J. Wang, *Biomaterials*, 2011, **32**, 3124–3133.
- 161 K. L. Kozielski, S. Y. Tzeng, B. A. Hurtado De Mendoza and J. J. Green, *ACS Nano*, 2014, **8**, 3232–3241.
- 162 V. Sava, O. Fihurka, A. Khvorova and J. Sanchez-Ramos, *Nanomedicine*, 2020, **24**, 102119.
- 163 S. An, D. He, E. Wagner and C. Jiang, *Small*, 2015, **11**, 5142–5150.

- 164 I.-D. Kim, C.-M. Lim, J.-B. Kim, H. Y. Nam, K. Nam, S.-W. Kim, J.-S. Park and J.-K. Lee, *J. Controlled Release*, 2010, **142**, 422–430.
- 165 A. P. Mann, P. Scodeller, S. Hussain, J. Joo, E. Kwon, G. B. Braun, T. Mölder, Z.-G. She, V. R. Kotamraju and B. Ranscht, *Nat. Commun.*, 2016, **7**, 1–11.
- 166 H. Lopez-Bertoni, K. L. Kozielski, Y. Rui, B. Lal, H. Vaughan, D. R. Wilson, N. Mihelson, C. G. Eberhart, J. Laterra and J. J. Green, *Nano Lett.*, 2018, **18**, 4086–4094.
- 167 S. Watanabe, K. Hayashi, K. Toh, H. J. Kim, X. Liu, H. Chaya, S. Fukushima, K. Katsushima, Y. Kondo and S. Uchida, *Nat. Commun.*, 2019, **10**, 1–13.
- 168 Z. Shatsberg, X. Zhang, P. Ofek, S. Malhotra, A. Krivitsky, A. Scomparin, G. Tiram, M. Calderón, R. Haag and R. Satchi-Fainaro, *J. Controlled Release*, 2016, **239**, 159–168.
- 169 M. Van Woensel, N. Wauthoz, R. Rosière, V. Mathieu, R. Kiss, F. Lefranc, B. Steelant, E. Dilissen, S. W. Van Gool and T. Mathivet, *J. Controlled Release*, 2016, **227**, 71–81.
- 170 Y. Yang, T. Du, J. Zhang, T. Kang, L. Luo, J. Tao, Z. Gou, S. Chen, Y. Du and J. He, *Adv. Sci.*, 2017, **4**, 1600491.
- 171 Y.-E. Seo, H.-W. Suh, R. Bahal, A. Josowitz, J. Zhang, E. Song, J. Cui, S. Noorbakhsh, C. Jackson and T. Bu, *Biomaterials*, 2019, **201**, 87–98.
- 172 X. J. Loh, T.-C. Lee, Q. Dou and G. R. Deen, *Biomater. Sci.*, 2016, **4**, 70–86.
- 173 F. Yin, B. Gu, Y. Lin, N. Panwar, S. C. Tjin, J. Qu, S. P. Lau and K.-T. Yong, *Coord. Chem. Rev.*, 2017, **347**, 77–97.
- 174 M. S. Shim and Y. J. Kwon, *Adv. Drug Delivery Rev.*, 2012, **64**, 1046–1059.
- 175 E. Keles, Y. Song, D. Du, W.-J. Dong and Y. Lin, *Biomater. Sci.*, 2016, **4**, 1291–1309.
- 176 I.-D. Kim, E. Sawicki, H.-K. Lee, E.-H. Lee, H. J. Park, P.-L. Han, K. Kim, H. Choi and J.-K. Lee, *Nanomedicine*, 2016, **12**, 1219–1229.
- 177 U. K. Sukumar, R. J. C. Bose, M. Malhotra, H. A. Babikir, R. Afjei, E. Robinson, Y. Zeng, E. Chang, F. Habte, R. Sinclair, S. S. Gambhir, T. F. Massoud and R. Paulmurugan, *Biomaterials*, 2019, **218**, 119342.
- 178 B. Yoo, M. A. Ifediba, S. Ghosh, Z. Medarova and A. Moore, *Mol. Imaging Biol.*, 2014, **16**, 680–689.
- 179 W. Y. Tong, M. Alnakhli, R. Bhardwaj, S. Apostolou, S. Sinha, C. Fraser, T. Kuchel, B. Kuss and N. H. Voelcker, *J. Nanobiotechnol.*, 2018, **16**, 38.
- 180 J. Jung, A. Solanki, K. A. Memoli, K.-i. Kamei, H. Kim, M. A. Drahl, L. J. Williams, H.-R. Tseng and K. Lee, *Angew. Chem., Int. Ed.*, 2010, **49**, 103–107.
- 181 C. Saraiva, J. Paiva, T. Santos, L. Ferreira and L. Bernardino, *J. Controlled Release*, 2016, **235**, 291–305.
- 182 F. M. Kievit, K. Wang, T. Ozawa, A. W. Tarudji, J. R. Silber, E. C. Holland, R. G. Ellenbogen and M. Zhang, *Nanomedicine*, 2017, **13**, 2131–2139.
- 183 D. Z. Liu, Y. Cheng, R. Q. Cai, W. W. Wang Bd, H. Cui, M. Liu, B. L. Zhang, Q. B. Mei and S. Y. Zhou, *Nanomedicine*, 2018, **14**, 991–1003.
- 184 L. L. Israel, A. Galstyan, E. Holler and J. Y. Ljubimova, *J. Controlled Release*, 2020, **320**, 45–62.
- 185 C. Qiao, J. Yang, Q. Shen, R. Liu, Y. Li, Y. Shi, J. Chen, Y. Shen, Z. Xiao, J. Weng and X. Zhang, *Adv. Mater.*, 2018, **30**, e1705054.
- 186 H. W. Yang, C. Y. Huang, C. W. Lin, H. L. Liu, C. W. Huang, S. S. Liao, P. Y. Chen, Y. J. Lu, K. C. Wei and C. C. Ma, *Biomaterials*, 2014, **35**, 6534–6542.
- 187 M. Zhou, N. Jiang, J. Fan, S. Fu, H. Luo, P. Su, M. Zhang, H. Shi, J. Zeng, Y. Huang, Y. Li, H. Shen, A. Zhang and R. Li, *J. Controlled Release*, 2019, **310**, 24–35.
- 188 E. Dirren, J. Aebischer, C. Rochat, C. Towne, B. L. Schneider and P. Aebischer, *Ann. Clin. Transl. Neurol.*, 2015, **2**, 167–184.
- 189 M. K. Keaveney, H.-a. Tseng, T. L. Ta, H. J. Gritton, H.-Y. Man and X. Han, *Cell Rep.*, 2018, **24**, 294–303.
- 190 Y. Shi, Y. Jiang, J. Cao, W. Yang, J. Zhang, F. Meng and Z. Zhong, *J. Controlled Release*, 2018, **292**, 163–171.
- 191 M. S. Sands and B. L. Davidson, *Mol. Ther.*, 2006, **13**, 839–849.
- 192 T. Ohashi, *J. Hum. Genet.*, 2019, **64**, 139–143.
- 193 E. L. Aronovich and P. B. Hackett, *Mol. Genet. Metab.*, 2015, **114**, 83–93.
- 194 G. Massaro, M. P. Hughes, S. M. Whaler, K.-L. Wallom, D. A. Priestman, F. M. Platt, S. N. Waddington and A. A. Rahim, *Hum. Mol. Genet.*, 2020, **29**, 1933–1949.
- 195 C. McIntyre, A. L. K. Derrick-Roberts, S. Byers and D. S. Anson, *J. Gene Med.*, 2014, **16**, 374–387.
- 196 M. Tardieu, M. Zerah, M. L. Gougeon, J. Ausseil, S. de Bournonville, B. Husson, D. Zafeiriou, G. Parenti, P. Bourget, B. Poirier, V. Furlan, C. Artaud, T. Bagnon, T. Roujeau, R. G. Crystal, C. Meyer, K. Deiva and J. M. Heard, *Lancet Neurol.*, 2017, **16**, 712–720.
- 197 R. J. Chandler, I. M. Williams, A. L. Gibson, C. D. Davidson, A. A. Incao, B. T. Hubbard, F. D. Porter, W. J. Pavan and C. P. Venditti, *Hum. Mol. Genet.*, 2017, **26**, 52–64.
- 198 M. P. Hughes, D. A. Smith, L. Morris, C. Fletcher, A. Colaco, M. Huebecker, J. Tordo, N. Palomar, G. Massaro, E. Henckaerts, S. N. Waddington, F. M. Platt and A. A. Rahim, *Hum. Mol. Genet.*, 2018, **27**, 3079–3098.
- 199 W. Poewe, K. Seppi, C. M. Tanner, G. M. Halliday, P. Brundin, J. Volkmann, A. E. Schrag and A. E. Lang, *Nat. Rev. Dis. Primers*, 2017, **3**, 17013.
- 200 W. L. Hwu, S. I. Muramatsu, S. H. Tseng, K. Y. Tzen, N. C. Lee, Y. H. Chien, R. O. Snyder, B. J. Byrne, C. H. Tai and R. M. Wu, *Sci. Transl. Med.*, 2012, **4**, 134ra61.
- 201 K. Kojima, T. Nakajima, N. Taga, A. Miyauchi, M. Kato, A. Matsumoto, T. Ikeda, K. Nakamura, T. Kubota, H. Mizukami, S. Ono, Y. Onuki, T. Sato, H. Osaka, S. I. Muramatsu and T. Yamagata, *Brain*, 2019, **142**, 322–333.
- 202 K. S. Bankiewicz, J. L. Eberling, M. Kohutnicka, W. Jagust, P. Pivrotto, J. Bringas, J. Cunningham, T. F. Budinger and J. Harvey-White, *Exp. Neurol.*, 2000, **164**, 2–14.

- 203 A. Nagarajan, R. Bodhicharla, J. Winter, C. Anbalagan, K. Morgan, M. Searle, A. Nazir, A. Adenle, A. Fineberg, D. Brady, K. Vere, J. Richens, P. O'Shea, D. Bell and D. de-Pomerai, *CNS Neurol. Disord.: Drug Targets*, 2015, **14**, 1054–1068.
- 204 M. Takahashi, M. Suzuki, M. Fukuoka, N. Fujikake, S. Watanabe, M. Murata, K. Wada, Y. Nagai and H. Hohjoh, *Mol. Ther.–Nucleic Acids*, 2015, **4**, e241.
- 205 J. H. Kordower, Isacson, Brooks, Olanow, Hunot, Stocchi, Jenner, Rascol and Marek, *Ann. Neurol.*, 2003, **53**, DOI: 10.1002/ana.10485.
- 206 J. S. Zheng, L. L. Tang, S. S. Zheng, R. Y. Zhan, Y. Q. Zhou, J. Goudreau, D. Kaufman and A. F. Chen, *Mol. Brain Res.*, 2005, **134**, 155–161.
- 207 P. Barroso-Chinea, I. Cruz-Muros, D. Afonso-Oramas, J. Castro-Hernandez, J. Salas-Hernandez, A. Chtarto, D. Luis-Ravelo, M. Humbert-Claude, L. Tenenbaum and T. Gonzalez-Hernandez, *Neurobiol. Dis.*, 2016, **88**, 44–54.
- 208 C. Warren Olanow, R. T. Bartus, T. L. Baumann, S. Factor, N. Boulis, M. Stacy, D. A. Turner, W. Marks, P. Larson, P. A. Starr, J. Jankovic, R. Simpson, R. Watts, B. Guthrie, K. Poston, J. M. Henderson, M. Stern, G. Baltuch, C. G. Goetz, C. Herzog, J. H. Kordower, R. Alterman, A. M. Lozano and A. E. Lang, *Ann. Neurol.*, 2015, **78**, 248–257.
- 209 W. J. Marks Jr., R. T. Bartus, J. Siffert, C. S. Davis, A. Lozano, N. Boulis, J. Vitek, M. Stacy, D. Turner, L. Verhagen, R. Bakay, R. Watts, B. Guthrie, J. Jankovic, R. Simpson, M. Tagliati, R. Alterman, M. Stern, G. Baltuch, P. A. Starr, P. S. Larson, J. L. Ostrem, J. Nutt, K. Kieburz, J. H. Kordower and C. W. Olanow, *Lancet Neurol.*, 2010, **9**, 1164–1172.
- 210 B. Hampoelz, A. Schwarz, P. Ronchi, H. Bragulat-Teixidor, C. Tischler, I. Gaspar, A. Ephrussi, Y. Schwab and M. Beck, *Cell*, 2019, **179**, 671–686.
- 211 M. T. Heneka, M. J. Carson, J. E. Khoury, G. E. Landreth, F. Brosseron, D. L. Feinstein, A. H. Jacobs, T. Wyss-Coray, J. Vitorica, R. M. Ransohoff, K. Herrup, S. A. Frautschy, B. Finsen, G. C. Brown, A. Verkhratsky, K. Yamanaka, J. Koistinaho, E. Latz, A. Halle, G. C. Petzold, T. Town, D. Morgan, M. L. Shinohara, V. H. Perry, C. Holmes, N. G. Bazan, D. J. Brooks, S. Hunot, B. Joseph, N. Deigendesch, O. Garaschuk, E. Boddeke, C. A. Dinarello, J. C. Breitner, G. M. Cole, D. T. Golenbock and M. P. Kummer, *Lancet Neurol.*, 2015, **14**, 388–405.
- 212 W. V. Graham, A. Bonito-Oliva and T. P. Sakmar, *Annu. Rev. Med.*, 2017, **68**, 413–430.
- 213 H. Zheng and E. H. Koo, *Mol. Neurodegener.*, 2011, **6**, 27.
- 214 D. E. Hurtado, L. Molina-Porcel, J. C. Carroll, C. Macdonald, A. K. Aboagye, J. Q. Trojanowski and V. M. Y. Lee, *J. Neurosci.*, 2012, **32**, 7392–7402.
- 215 M. H. Tuszynski, L. Thal, M. Pay, D. P. Salmon, H. Sang, U. R. Bakay, P. Patel, A. Blesch, H. L. Vahlsing, G. Ho, G. Tong, S. G. Potkin, J. Fallon, L. Hansen, E. J. Mufson, J. H. Kordower, C. Gall and J. Conner, *Nat. Med.*, 2005, **11**, 551–555.
- 216 M. H. Tuszynski, J. H. Yang, D. Barba, U. Hoi-Sang, R. A. E. Bakay, M. M. Pay, E. Masliah, J. M. Conner, P. Kobalka, S. Roy and A. H. Nagahara, *JAMA Neurol.*, 2015, **72**, 1139–1147.
- 217 D. Hanahan and R. A. Weinberg, *Cell*, 2011, **144**, 646–674.
- 218 S. L. Ginn, A. K. Amaya, I. E. Alexander, M. Edelstein and M. R. Abedi, *J. Gene Med.*, 2018, **20**, e3015–e3015.
- 219 H. Ito, T. Kanzawa, T. Miyoshi, S. Hirohata, S. Kyo, A. Iwamaru, H. Aoki, Y. Kondo and S. Kondo, *Hum. Gene Ther.*, 2005, **16**, 685–698.
- 220 T. Ozawa, J. L. Hu, L. J. Hu, E. L. Kong, A. W. Bollen, K. R. Lamborn and D. F. Deen, *Cancer Gene Ther.*, 2005, **12**, 449–455.
- 221 H. Tsurushima, X. Yuan, L. E. Dillehay and K. W. Leong, *Cancer Gene Ther.*, 2007, **14**, 706–716.
- 222 N. Ji, D. Weng, C. Liu, Z. Gu, S. Chen, Y. Guo, Z. Fan, X. Wang, J. Chen, Y. Zhao, J. Zhou, J. Wang, D. Ma and N. Li, *Oncotarget*, 2016, **7**, 4369–4378.
- 223 C. N. Chao, Y. H. Yang, M. S. Wu, M. C. Chou, C. Y. Fang, M. C. Lin, C. K. Tai, C. H. Shen, P. L. Chen, D. Chang and M. Wang, *Sci. Rep.*, 2018, **8**, 1–11.
- 224 T. A. Cheema, R. Kanai, G. W. Kim, H. Wakimoto, B. Passer, S. D. Rabkin and R. L. Martuza, *Clin. Cancer Res.*, 2011, **17**, 7383–7393.
- 225 J. Martinez-Quintanilla, D. He, H. Wakimoto, R. Alemany and K. Shah, *Mol. Ther.*, 2015, **23**, 108–118.
- 226 A. J. Brenner, K. B. Peters, J. Vredenburg, F. Bokstein, D. T. Blumenthal, S. Yust-Katz, I. Peretz, B. Oberman, L. S. Freedman, B. M. Ellingson, T. F. Cloughesy, N. Sher, Y. C. Cohen, N. Lowenton-Spier, T. Rachmilewitz Minei, N. Yakov, I. Mendel, E. Breitbart and P. Y. Wen, *Neuro-Oncology*, 2019, **22**, 694–704.
- 227 Z. Zhang, Z. Zhu, K. Watabe, X. Zhang, C. Bai, M. Xu, F. Wu and Y. Y. Mo, *Cell Death Differ.*, 2013, **20**, 1558–1568.
- 228 R. El Fatimy, S. Subramanian, E. J. Uhlmann and A. M. Krichevsky, *Mol. Ther.*, 2017, **25**, 368–378.
- 229 S. Ito, A. Natsume, S. Shimato, M. Ohno, T. Kato, P. Chansakul, T. Wakabayashi and S. U. Kim, *Cancer Gene Ther.*, 2010, **17**, 299–306.
- 230 D. GuhaSarkar, J. Neiswender, Q. Su, G. Gao and M. Sena-Esteves, *Mol. Oncol.*, 2017, **11**, 180–193.
- 231 D. E. Hurtado, L. Molina-Porcel, J. C. Carroll, C. MacDonald, A. K. Aboagye, J. Q. Trojanowski and V. M.-Y. Lee, *J. Neurosci.*, 2012, **32**, 7392–7402.
- 232 Y.-X. Yong, Y.-M. Li, J. Lian, C.-M. Luo, D.-X. Zhong and K. Han, *J. Cell. Biochem.*, 2019, **120**, 368–379.
- 233 M. M. Evers, J. Miniarikova, S. Juhas, A. Vallès, B. Bohuslavova, J. Juhasova, H. K. Skalninkova, P. Vodicka, I. Valekova, C. Brouwers, B. Blits, J. Lubelski, H. Kovarova, Z. Ellederova, S. J. van Deventer, H. Petry, J. Motlik and P. Konstantinova, *Mol. Ther.*, 2018, **26**, 2163–2177.
- 234 L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhali and M. J. A. Wood, *Nat. Biotechnol.*, 2011, **29**, 341–345.
- 235 W. Y. Tong, M. Alnakhl, R. Bhardwaj, S. Apostolou, S. Sinha, C. Fraser, T. Kuchel, B. Kuss and N. H. Voelcker, *J. Nanobiotechnol.*, 2018, **16**, 38.

- 236 M. Campbell, F. Hanrahan, O. L. Gobbo, M. E. Kelly, A.-S. Kiang, M. M. Humphries, A. T. H. Nguyen, E. Ozaki, J. Keaney, C. W. Blau, C. M. Kerskens, S. D. Cahalan, J. J. Callanan, E. Wallace, G. A. Grant, C. P. Doherty and P. Humphries, *Nat. Commun.*, 2012, **3**, 849.
- 237 Y.-E. Seo, H.-W. Suh, R. Bahal, A. Josowitz, J. Zhang, E. Song, J. Cui, S. Noorbakhsh, C. Jackson, T. Bu, A. Piotrowski-Daspiet, R. Bindra and W. M. Saltzman, *Biomaterials*, 2019, **201**, 87–98.
- 238 M. Rodriguez, J. Lapierre, C. R. Ojha, A. Kaushik, E. Batrakova, F. Kashanchi, S. M. Dever, M. Nair and N. El-Hage, *Sci. Rep.*, 2017, **7**, 1862.
- 239 J. F. Alterman, L. M. Hall, A. H. Coles, M. R. Hassler, M.-C. Didiot, K. Chase, J. Abraham, E. Sottosanti, E. Johnson, E. Sapp, M. F. Osborn, M. Difiglia, N. Aronin and A. Khvorova, *Mol. Ther.–Nucleic Acids*, 2015, **4**, e266.
- 240 H. Zhang, Y. Lin, Y. Qu and Q. Chen, *Eur. Rev. Med. Pharmacol. Sci.*, 2018, **22**, 2372–2379.
- 241 C. L. Esposito, S. Nuzzo, S. Catuogno, S. Romano, F. de Nigris and V. de Franciscis, *Mol. Ther.–Nucleic Acids*, 2018, **10**, 398–411.
- 242 F. D. Urnov, J. C. Miller, Y.-L. Lee, C. M. Beausejour, J. M. Rock, S. Augustus, A. C. Jamieson, M. H. Porteus, P. D. Gregory and M. C. Holmes, *Nature*, 2005, **435**, 646–651.
- 243 J. Boch, H. Scholze, S. Schornack, A. Landgraf, S. Hahn, S. Kay, T. Lahaye, A. Nickstadt and U. Bonas, *Science*, 2009, **326**, 1509–1512.
- 244 J. C. Miller, S. Tan, G. Qiao, K. A. Barlow, J. Wang, D. F. Xia, X. Meng, D. E. Paschon, E. Leung, S. J. Hinkley, G. P. Dulay, K. L. Hua, I. Ankoudinova, G. J. Cost, F. D. Urnov, H. S. Zhang, M. C. Holmes, L. Zhang, P. D. Gregory and E. J. Rebar, *Nat. Biotechnol.*, 2011, **29**, 143–148.
- 245 M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna and E. Charpentier, *Science*, 2012, **337**, 816–821.
- 246 P. Mali, L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville and G. M. Church, *Science*, 2013, **339**, 823–826.
- 247 T. Gaj, S. J. Sirk, S.-L. Shui and J. Liu, *Cold Spring Harbor Perspect. Biol.*, 2016, **8**, a023754.
- 248 M. Heidenreich and F. Zhang, *Nat. Rev. Neurosci.*, 2016, **17**, 36–44.
- 249 K. Rodgers and M. McVey, *J. Cell Physiol.*, 2016, **231**, 15–24.
- 250 M. Garriga-Canut, C. Agustín-Pavón, F. Herrmann, A. Sánchez, M. Dierssen, C. Fillat and M. Isalan, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, E3136–E3145.
- 251 B. Zeitler, S. Froelich, K. Marlen, D. A. Shivak, Q. Yu, D. Li, J. R. Pearl, J. C. Miller, L. Zhang, D. E. Paschon, S. J. Hinkley, I. Ankoudinova, S. Lam, D. Guschin, L. Kopan, J. M. Cherone, H. B. Nguyen, G. Qiao, Y. Ataei, M. C. Mendel, R. Amora, R. Surosky, J. Laganier, B. J. Vu, A. Narayanan, Y. Sedaghat, K. Tillack, C. Thiede, A. Gartner, S. Kwak, J. Bard, L. Mrzljak, L. Park, T. Heikkinen, K. K. Lehtimäki, M. M. Svedberg, J. Haggkvist, L. Tari, M. Toth, A. Varrone, C. Halldin, A. E. Kudwa, S. Ramboz, M. Day, J. Kondapalli, D. J. Surmeier, F. D. Urnov, P. D. Gregory, E. J. Rebar, I. Munoz-Sanjuan and H. S. Zhang, *Nat. Med.*, 2019, **25**, 1131–1142.
- 252 C. Agustin-Pavon, M. Mielcarek, M. Garriga-Canut and M. Isalan, *Mol. Neurodegener.*, 2016, **11**, 64.
- 253 M. Zahur, J. Tolö, M. Bähr and S. Kügler, *Front. Mol. Neurosci.*, 2017, **10**, 142–142.
- 254 M. J. Moscou and A. J. Bogdanove, *Science*, 2009, **326**, 1501.
- 255 L. Cong, R. Zhou, Y.-C. Kuo, M. Cunniff and F. Zhang, *Nat. Commun.*, 2012, **3**, 968–968.
- 256 M. L. Maeder, S. J. Linder, D. Reyon, J. F. Angstman, Y. Fu, J. D. Sander and J. K. Joung, *Nat. Methods*, 2013, **10**, 243–245.
- 257 V. M. Bedell, Y. Wang, J. M. Campbell, T. L. Poshusta, C. G. Starker, R. G. Krug, 2nd, W. Tan, S. G. Penheiter, A. C. Ma, A. Y. Leung, S. C. Fahrenkrug, D. F. Carlson, D. F. Voytas, K. J. Clark, J. J. Essner and S. C. Ekker, *Nature*, 2012, **491**, 114–118.
- 258 Z. Qiu, M. Liu, Z. Chen, Y. Shao, H. Pan, G. Wei, C. Yu, L. Zhang, X. Li, P. Wang, H. Y. Fan, B. Du, B. Liu, M. Liu and D. Li, *Nucleic Acids Res.*, 2013, **41**, e120.
- 259 F. A. Ran, L. Cong, W. X. Yan, D. A. Scott, J. S. Gootenberg, A. J. Kriz, B. Zetsche, O. Shalem, X. Wu, K. S. Makarova, E. V. Koonin, P. A. Sharp and F. Zhang, *Nature*, 2015, **520**, 186–191.
- 260 J. A. Doudna and E. Charpentier, *Science*, 2014, **346**, 1258096.
- 261 L. A. Gilbert, M. H. Larson, L. Morsut, Z. Liu, G. A. Brar, S. E. Torres, N. Stern-Ginossar, O. Brandman, E. H. Whitehead, J. A. Doudna, W. A. Lim, J. S. Weissman and L. S. Qi, *Cell*, 2013, **154**, 442–451.
- 262 L. A. Gilbert, M. A. Horlbeck, B. Adamson, J. E. Villalta, Y. Chen, E. H. Whitehead, C. Guimaraes, B. Panning, H. L. Ploegh, M. C. Bassik, L. S. Qi, M. Kampmann and J. S. Weissman, *Cell*, 2014, **159**, 647–661.
- 263 Y. Zheng, W. Shen, J. Zhang, B. Yang, Y.-N. Liu, H. Qi, X. Yu, S.-Y. Lu, Y. Chen, Y.-Z. Xu, Y. Li, F. H. Gage, S. Mi and J. Yao, *Nat. Neurosci.*, 2018, **21**, 447–454.
- 264 H. Zhou, J. Liu, C. Zhou, N. Gao, Z. Rao, H. Li, X. Hu, C. Li, X. Yao, X. Shen, Y. Sun, Y. Wei, F. Liu, W. Ying, J. Zhang, C. Tang, X. Zhang, H. Xu, L. Shi, L. Cheng, P. Huang and H. Yang, *Nat. Neurosci.*, 2018, **21**, 440–446.
- 265 S. M. Heman-Ackah, A. R. Bassett and M. J. A. Wood, *Sci. Rep.*, 2016, **6**, 28420–28420.
- 266 F. K. Ekman, D. S. Ojala, M. M. Adil, P. A. Lopez, D. V. Schaffer and T. Gaj, *Mol. Ther.–Nucleic Acids*, 2019, **17**, 829–839.
- 267 J. W. Shin, K.-H. Kim, M. J. Chao, R. S. Atwal, T. Gillis, M. E. MacDonald, J. F. Gusella and J.-M. Lee, *Hum. Mol. Genet.*, 2016, **25**, 4566–4576.
- 268 A. M. Monteys, S. A. Ebanks, M. S. Keiser and B. L. Davidson, *Mol. Ther.*, 2017, **25**, 12–23.

- 269 S. Yang, R. Chang, H. Yang, T. Zhao, Y. Hong, H. E. Kong, X. Sun, Z. Qin, P. Jin, S. Li and X.-J. Li, *J. Clin. Invest.*, 2017, **127**, 2719–2724.
- 270 B. György, C. Lööv, M. P. Zaborowski, S. Takeda, B. P. Kleinstiver, C. Commings, K. Kastanenka, D. Mu, A. Volak, V. Giedraitis, L. Lannfelt, C. A. Maguire, J. K. Joung, B. T. Hyman, X. O. Breakefield and M. Ingelsson, *Mol. Ther.–Nucleic Acids*, 2018, **11**, 429–440.
- 271 H. Park, J. Oh, G. Shim, B. Cho, Y. Chang, S. Kim, S. Baek, H. Kim, J. Shin, H. Choi, J. Yoo, J. Kim, W. Jun, M. Lee, C. J. Lengner, Y. K. Oh and J. Kim, *Nat. Neurosci.*, 2019, **22**, 524–528.
- 272 B. Lee, K. Lee, S. Panda, R. Gonzales-Rojas, A. Chong, V. Bugay, H. M. Park, R. Brenner, N. Murthy and H. Y. Lee, *Nat. Biomed. Eng.*, 2018, **2**, 497–507.
- 273 S. C. Vermilyea, A. Babinski, N. Tran, S. To, S. Guthrie, J. H. Kluss, J. K. Schmidt, G. J. Wiep, M. G. Meyer, M. E. Murphy, M. R. Cookson, M. E. Emborg and T. G. Golos, *Sci. Rep.*, 2020, **10**, 3447.
- 274 J. Arias-Fuenzalida, J. Jarazo, X. Qing, J. Walter, G. Gomez-Giro, S. L. Nickels, H. Zaehres, H. R. Scholer and J. C. Schwamborn, *Stem Cell Rep.*, 2017, **9**, 1423–1431.
- 275 G. Murlidharan, K. Sakamoto, L. Rao, T. Corriher, D. Wang, G. Gao, P. Sullivan and A. Asokan, *Mol. Ther.–Nucleic Acids*, 2016, **5**, e338–e338.
- 276 N. Kalebic, E. Taverna, S. Tavano, F. K. Wong, D. Suchold, S. Winkler, W. B. Huttner and M. Sarov, *EMBO Rep.*, 2016, **17**, 338–348.
- 277 S. Back, J. Necarsulmer, L. R. Whitaker, L. M. Coke, P. Koivula, E. J. Heathward, L. V. Fortuno, Y. Zhang, C. G. Yeh, H. A. Baldwin, M. D. Spencer, C. A. Mejias-Aponte, J. Pickel, A. F. Hoffman, C. E. Spivak, C. R. Lupica, S. M. Underhill, S. G. Amara, A. Domanskyi, J. E. Anttila, M. Airavaara, B. T. Hope, F. K. Hamra, C. T. Richie and B. K. Harvey, *Neuron*, 2019, **102**, 105–119.
- 278 H. Sun, S. Fu, S. Cui, X. Yin, X. Sun, X. Qi, K. Cui, J. Wang, L. Ma, F.-Y. Liu, F.-F. Liao, X.-H. Wang, M. Yi and Y. Wan, *Sci. Adv.*, 2020, **6**, eaay6687.
- 279 W. Yang, Y. Liu, Z. Tu, C. Xiao, S. Yan, X. Ma, X. Guo, X. Chen, P. Yin, Z. Yang, S. Yang, T. Jiang, S. Li, C. Qin and X. J. Li, *Cell Res.*, 2019, **29**, 334–336.
- 280 T. Mikuni, J. Nishiyama, Y. Sun, N. Kamasawa and R. Yasuda, *Cell*, 2016, **165**, 1803–1817.
- 281 K. Suzuki, Y. Tsunekawa, R. Hernandez-Benitez, J. Wu, J. Zhu, E. J. Kim, F. Hatanaka, M. Yamamoto, T. Araoka, Z. Li, M. Kurita, T. Hishida, M. Li, E. Aizawa, S. Guo, S. Chen, A. Goebel, R. D. Soligalla, J. Qu, T. Jiang, X. Fu, M. Jafari, C. R. Esteban, W. T. Berggren, J. Lajara, E. Nuñez-Delicado, P. Guillen, J. M. Campistol, F. Matsuzaki, G.-H. Liu, P. Magistretti, K. Zhang, E. M. Callaway, K. Zhang and J. C. I. Belmonte, *Nature*, 2016, **540**, 144–149.
- 282 L. Swiech, M. Heidenreich, A. Banerjee, N. Habib, Y. Li, J. Trombetta, M. Sur and F. Zhang, *Nat. Biotechnol.*, 2015, **33**, 102–106.
- 283 B. T. Staahl, M. Benekareddy, C. Coulon-Bainier, A. A. Banfal, S. N. Floor, J. K. Sabo, C. Urnes, G. A. Munares, A. Ghosh and J. A. Doudna, *Nat. Biotechnol.*, 2017, **35**, 431–434.
- 284 J. Nishiyama, T. Mikuni and R. Yasuda, *Neuron*, 2017, **96**, 755–768.
- 285 X. Xu, T. Wan, H. Xin, D. Li, H. Pan, J. Wu and Y. Ping, *J. Gene Med.*, 2019, **21**, e3107.
- 286 D. P. Dever, S. G. Scharenberg, J. Camarena, E. J. Kildebeck, J. T. Clark, R. M. Martin, R. O. Bak, Y. Tang, M. Dohse, J. A. Birgmeier, K. A. Jagadeesh, G. Bejerano, A. Tsukamoto, N. Gomez-Ospina, N. Uchida and M. H. Porteus, *iScience*, 2019, **15**, 524–535.
- 287 H. Yang, H. Wang, C. S. Shivalila, A. W. Cheng, L. Shi and R. Jaenisch, *Cell*, 2013, **154**, 1370–1379.
- 288 T. Horii, Y. Arai, M. Yamazaki, S. Morita, M. Kimura, M. Itoh, Y. Abe and I. Hatada, *Sci. Rep.*, 2014, **4**, 4513–4513.
- 289 M. Zuckermann, V. Hovestadt, C. B. Knobbe-Thomsen, M. Zapatka, P. A. Northcott, K. Schramm, J. Belic, D. T. W. Jones, B. Tschida, B. Moriarity, D. Largaespada, M. F. Roussel, A. Korshunov, G. Reifemberger, S. M. Pfister, P. Lichter, D. Kawauchi and J. Gronych, *Nat. Commun.*, 2015, **6**, 7391.
- 290 M. Kumar, B. Keller, N. Makalou and R. E. Sutton, *Hum. Gene Ther.*, 2001, **12**, 1893–1905.
- 291 S. Incontro, C. S. Asensio, R. H. Edwards and R. A. Nicoll, *Neuron*, 2014, **83**, 1051–1057.
- 292 R. J. Platt, S. Chen, Y. Zhou, M. J. Yim, L. Swiech, H. R. Kempton, J. E. Dahlman, O. Parnas, T. M. Eisenhaure, M. Jovanovic, D. B. Graham, S. Jhunjhunwala, M. Heidenreich, R. J. Xavier, R. Langer, D. G. Anderson, N. Hacohen, A. Regev, G. Feng, P. A. Sharp and F. Zhang, *Cell*, 2014, **159**, 440–455.
- 293 N. Kumar, W. Stanford, C. de Solis, Aradhana, N. D. Abraham, T.-M. J. Dao, S. Thaseen, A. Sairavi, C. U. Gonzalez and J. E. Ploski, *Front. Mol. Neurosci.*, 2018, **11**, 413–413.
- 294 G. Chen, A. A. Abdeen, Y. Wang, P. K. Shahi, S. Robertson, R. Xie, M. Suzuki, B. R. Pattnaik, K. Saha and S. Gong, *Nat. Nanotechnol.*, 2019, **14**, 974–980.
- 295 K. Y. Chan, M. J. Jang, B. B. Yoo, A. Greenbaum, N. Ravi, W. L. Wu, L. Sanchez-Guardado, C. Lois, S. K. Mazmanian, B. E. Deverman and V. Gradinaru, *Nat. Neurosci.*, 2017, **20**, 1172–1179.
- 296 K. S. Hanlon, B. P. Kleinstiver, S. P. Garcia, M. P. Zaborowski, A. Volak, S. E. Spirig, A. Muller, A. A. Sousa, S. Q. Tsai, N. E. Bengtsson, C. Loov, M. Ingelsson, J. S. Chamberlain, D. P. Corey, M. J. Aryee, J. K. Joung, X. O. Breakefield, C. A. Maguire and B. Gyorgy, *Nat. Commun.*, 2019, **10**, 4439.
- 297 H. C. Verdera, K. Kuranda and F. Mingozzi, *Mol. Ther.*, 2020, **28**, 723–746.
- 298 N. Merienne, G. Vachey, L. de Longprez, C. Meunier, V. Zimmer, G. Perriard, M. Canales, A. Mathias, L. Herrgott, T. Beltraminelli, A. Maulet, T. Dequesne,

- C. Pythoud, M. Rey, L. Pellerin, E. Brouillet, A. L. Perrier, R. du Pasquier and N. Déglon, *Cell Rep.*, 2017, **20**, 2980–2991.
- 299 S. Yang, S. Li and X.-J. Li, *Cell Rep.*, 2018, **25**, 2653–2659.
- 300 G. Murlidharan, K. Sakamoto, L. Rao, T. Corriher, D. Wang, G. Gao, P. Sullivan and A. Asokan, *Mol. Ther.–Nucleic Acids*, 2016, **5**, e338–e338.
- 301 H. Yin, C.-Q. Song, J. R. Dorkin, L. J. Zhu, Y. Li, Q. Wu, A. Park, J. Yang, S. Suresh, A. Bizhanova, A. Gupta, M. F. Bolukbasi, S. Walsh, R. L. Bogorad, G. Gao, Z. Weng, Y. Dong, V. Koteliensky, S. A. Wolfe, R. Langer, W. Xue and D. G. Anderson, *Nat. Biotechnol.*, 2016, **34**, 328–333.
- 302 W. Sun, W. Ji, J. M. Hall, Q. Hu, C. Wang, C. L. Beisel and Z. Gu, *Angew. Chem., Int. Ed.*, 2015, **54**, 12029–12033.
- 303 S. Ramakrishna, A.-B. Kwaku Dad, J. Beloor, R. Gopalappa, S.-K. Lee and H. Kim, *Genome Res.*, 2014, **24**, 1020–1027.
- 304 K. Lee, M. Conboy, H. M. Park, F. Jiang, H. J. Kim, M. A. Dewitt, V. A. Mackley, K. Chang, A. Rao, C. Skinner, T. Shobha, M. Mehdi pour, H. Liu, W.-c. Huang, F. Lan, N. L. Bray, S. Li, J. E. Corn, K. Kataoka, J. A. Doudna, I. Conboy and N. Murthy, *Nat. Biomed. Eng.*, 2017, **1**, 889–901.
- 305 P. Gee, M. S. Y. Lung, Y. Okuzaki, N. Sasakawa, T. Iguchi, Y. Makita, H. Hozumi, Y. Miura, L. F. Yang, M. Iwasaki, X. H. Wang, M. A. Waller, N. Shirai, Y. O. Abe, Y. Fujita, K. Watanabe, A. Kagita, K. A. Iwabuchi, M. Yasuda, H. Xu, T. Noda, J. Komano, H. Sakurai, N. Inukai and A. Hotta, *Nat. Commun.*, 2020, **11**, 1334.
- 306 R. Shahbazi, G. Sghia-Hughes, J. L. Reid, S. Kubek, K. G. Haworth, O. Humbert, H.-P. Kiem and J. E. Adair, *Nat. Mater.*, 2019, **18**, 1124–1132.
- 307 A. Kaushik, A. Yndart, V. Atluri, S. Tiwari, A. Tomitaka, P. Gupta, R. D. Jayant, D. Alvarez-Carbonell, K. Khalili and M. Nair, *Sci. Rep.*, 2019, **9**, 3928.
- 308 A. M. Monteys, S. A. Ebanks, M. S. Keiser and B. L. Davidson, *Mol. Ther.*, 2017, **25**, 12–23.
- 309 F. K. Ekman, D. S. Ojala, M. M. Adil, P. A. Lopez, D. V. Schaffer and T. Gaj, *Mol. Ther.–Nucleic Acids*, 2019, **17**, 829–839.
- 310 L. Ye, J. J. Park, M. B. Dong, Q. Yang, R. D. Chow, L. Peng, Y. Du, J. Guo, X. Dai, G. Wang, Y. Errami and S. Chen, *Nat. Biotechnol.*, 2019, **37**, 1302–1313.
- 311 C. Straub, A. J. Granger, J. L. Saulnier and B. L. Sabatini, *PLoS One*, 2014, **9**, e105584–e105584.
- 312 Y. Shinmyo, S. Tanaka, S. Tsunoda, K. Hosomichi, A. Tajima and H. Kawasaki, *Sci. Rep.*, 2016, **6**, 20611.
- 313 C. Praça, A. Rai, T. Santos, A. C. Cristovão, S. L. Pinho, R. Cecchelli, M.-P. Dehouck, L. Bernardino and L. S. Ferreira, *J. Controlled Release*, 2018, **284**, 57–72.
- 314 N. Lipsman, Y. Meng, A. J. Bethune, Y. Huang, B. Lam, M. Masellis, N. Herrmann, C. Heyn, I. Aubert, A. Boutet, G. S. Smith, K. Hynynen and S. E. Black, *Nat. Commun.*, 2018, **9**, 2336.
- 315 T.-E. Park, N. Mustafaoglu, A. Herland, R. Hasselkus, R. Mannix, E. A. FitzGerald, R. Prantil-Baun, A. Watters, O. Henry, M. Benz, H. Sanchez, H. J. McCrea, L. C. Goumnerova, H. W. Song, S. P. Palecek, E. Shusta and D. E. Ingber, *Nat. Commun.*, 2019, **10**, 2621.
- 316 C. Praça, S. C. Rosa, E. Sevin, R. Cecchelli, M.-P. Dehouck and L. S. Ferreira, *Stem Cell Rep.*, 2019, **13**, 599–611.
- 317 J. Feng, S. Lepetre-Mouelhi, A. Gautier, S. Mura, C. Cailleau, F. Coudore, M. Hamon and P. Couvreur, *Sci. Adv.*, 2019, **5**, eaau5148.
- 318 A. Joseph, C. Contini, D. Cecchin, S. Nyberg, L. Ruiz-Perez, J. Gaitzsch, G. Fullstone, X. Tian, J. Azizi, J. Preston, G. Volpe and G. Battaglia, *Sci. Adv.*, 2017, **3**, e1700362.
- 319 ClinicalTrials.gov, <https://clinicaltrials.gov/ct2/show/NCT04167540>, accessed 22 July 2020.
- 320 ClinicalTrials.gov, <https://clinicaltrials.gov/ct2/show/NCT03634007>, accessed 22 July 2020.
- 321 ClinicalTrials.gov, <https://clinicaltrials.gov/ct2/show/NCT04133454>, accessed 22 July 2020.
- 322 ClinicalTrials.gov, <https://clinicaltrials.gov/ct2/show/NCT03952637>, accessed 22 July 2020.
- 323 ClinicalTrials.gov, <https://clinicaltrials.gov/ct2/show/NCT03725670>, accessed 22 July 2020.
- 324 E. A. Stadtmauer, J. A. Fraietta, M. M. Davis, A. D. Cohen, K. L. Weber, E. Lancaster, P. A. Mangan, I. Kulikovskaya, M. Gupta, F. Chen, L. Tian, V. E. Gonzalez, J. Xu, I.-y. Jung, J. J. Melenhorst, G. Plesa, J. Shea, T. Matlawski, A. Cervini, A. L. Gaymon, S. Desjardins, A. Lamontagne, J. Salas-Mckee, A. Fesnak, D. L. Siegel, B. L. Levine, J. K. Jadowsky, R. M. Young, A. Chew, W.-T. Hwang, E. O. Hexner, B. M. Carreno, C. L. Nobles, F. D. Bushman, K. R. Parker, Y. Qi, A. T. Satpathy, H. Y. Chang, Y. Zhao, S. F. Lacey and C. H. June, *Science*, 2020, **367**, eaba7365.
- 325 Alnylam, <https://www.alnylam.com/>, accessed 23 July 2020.